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ABSTRACT
A novel role of human DNA damage checkpoint protein ATR in suppressing Ca2+
overload-induced PARP1-mediated necrosis
by
Hui Wang-Heaton
Ataxia telangiectasia and Rad3-related (ATR) is well known for its regulatory role in
DNA damage responses (DDR) as a checkpoint kinase that phosphorylates hundreds of
protein substrates. However, its role in cellular non-DNA damage stress responses
(NDDR) is unknown. Necrosis is one form of cell death and traditionally has been
regarded as a passive and uncontrolled cell death. Recently, evidence has emerged to
support the concept that necrosis also may occur in a programmed manner and that poly
(ADP-ribose) polymerase 1 (PARP1) can be a mediator. Active PARP1 hydrolyzes
nicotinamide adenine dinucleotide (NAD+) to produce poly (ADP-ribose) (PAR)
polymers on target proteins or itself. As a result, hyper-activity of PARP1 may lead to
necrosis by excessively depleting ATP pool which results in mitochondrial energetic
collapse. On the other hand, it is known that Ca2+ overload induces necrosis, but much
still remains unknown about how Ca2+ overload-induced necrosis is regulated in cells. In
this study, we show that ATR, besides its hallmark regulatory role in DDR, also plays a
role in NDDR by suppressing ionomycin-induced necrosis. Ionomycin as a Ca2+
ionophore can dramatically raise the intracellular level of Ca2+, leading to necrosis. We
found that this Ca2+ overload-induced necrosis occurs without inducing DDR in cells.
Instead, the hyper-poly(ADP-ribosyl)ation (PARylation) activity of activated PARP1
2

could be a reason leading to necrosis, as NAD+ supplied to media can rescue ionomycininduced necrosis. In vitro PARylation assay also demonstrates that PARP1 hyperactivation is Ca2+ dependent. In cells, ATR-PARP1 interaction happened after ionomycin
treatment. Furthermore, ionomycin treatment induces more full-length PAR polymers
formed in ATR-deficient cells than in ATR-proficient cells. The interaction of kinasedead ATR and PARP1 dramatically decreased as compared to wild-type ATR. Therefore,
ATR plays a novel role in NDDR wherein it is able to suppress Ca2+ overload-induced
PARP1-mediated necrosis. Ca2+ overload-induced cell death is a major cause of many
human medical conditions and diseases, such as brain injury, stroke and ischemia etc.
Our ongoing studies will help to define the molecular mechanisms of the anti-necrosis
activities of ATR, which may support ATR as a new clinical target for therapeutic
treatment of those diseases.
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CHAPTER 1
INTRODUCTION

DNA Damage Checkpoint Kinase ATR

ATR, ataxia telangiectasia and Rad3-related, is well known for its regulatory role
in the DNA damage responses (DDR). Its critical function has been shown in maintaining
genome integrity against DNA damage induced by endogenous or environmental sources
(Nyberg et al. 2002; Zou and Elledge 2003; Cimprich and Cortez 2008). Upon induction
of genomic stress, ATR and ataxia telangiectasia mutated (ATM) activate the
checkpoint-signaling pathway to induce cell cycle arrest, DNA repair, and/or apoptosis to
eliminate the damaged cells (Sancar et al. 2004; Wu et al. 2006) (Figure 1).

Figure 1: Schematic of DNA damage checkpoint activation following IR/UV
radiation (Used with permission by Dr. Yue Zou).
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ATR and ATM are two members of the phosphoinositide 3-kinase-related protein
kinase (PIKK) family of protein kinases and are the sensors of genomic stress (Abraham
2001) (Figure 1). ATR is activated by DNA damage-induced replicative stress, while
ATM is primarily activated by DNA double-strand breaks (DSBs) (Smith et al. 2010;
Zeman and Cimprich 2014). ATR detects genomic stress and then regulates the cellular
signaling pathways by phosphorylating downstream protein substrates. Chk1 and p53 are
two major substrates of ATR (Tibbetts et al. 1999; Liu et al. 2000; Toledo et al. 2011)
(Figure 1). ATR, as a checkpoint kinase, preferentially phosphorylates its substrates on
serine or threonine residues that are followed by a glutamine residue (SQ/TQ motif) (Kim
et al. 1999; Traven and Heierhorst 2005; O’Neill et al. 2000). For example, ATR
phosphorylates p53 at serine 15 and Chk1 at serine 345, which are all followed by a
glutamine residue (Tibbetts et al. 1999; Liu et al. 2000; Toledo et al. 2011).

Mechanisms of ATR Activation in DDR
As mentioned above, ATR primarily responses to DNA damage-induced
replicative stress and single-stranded DNA (ssDNA) (Burrows and Elledge 2008) (Figure
2). Replication protein A (RPA), is a ssDNA-binding protein, which binds at sites of
DNA damage-induced ssDNA. ATR interacting protein (ATRIP), the regulatory partner
of ATR, interacts with RPA and then ATR-ATRIP protein complex is recruited to sites of
DNA damage (Laplante and Sabatini 2009; Smith et al. 2010; Liu et al. 2012) (Figure 2).
In other words, RPA-mediated recruitment of ATR-ATRIP protein complex to ssDNA is
needed for ATR kinase activation in human cells (Zou and Elledge 2003; Namiki and
Zou 2006; Cortez 2001). DNA topoisomerase II binding protein 1 (TopBP1) later is
17

recruited to the ssDNA site to interact with ATR-ATRIP protein complex. The ATRactivating domain (AAD) of TopBP1 stimulates the kinase activity of ATR for the
phosphorylation of ATR’s substrates like Chk1 (Higgs and Peterson 2005; Kumagai et al.
2006; Ball et al. 2007, Xu and Leffak 2010) . It was reported that the AAD of TopBP1 is
important for the stimulation of ATR-ATRIP activity for DNA-damage-checkpoint
activation (Kumagai et al. 2006). Interestingly, TopBP1 is phosphorylated by ATR and
the phosphorylation on TopBP1 enhances the interaction between TopBP1 and ATRATRIP. TopBP1 activates the ATR-ATRIP complex, which is followed by ATR
phosphorylation of TopBP1. This phenomenon promotes a positive feedback loop to
amplify ATR-mediated DNA damage checkpoint signaling (Yoo et al. 2007).

Figure 2: ATR activation in conserved ATR-Chk1 checkpoint signaling
pathway (modified from Xu and Leffak 2010). ATR-ATRIP is recruited to
RPA-coated ssDNA by interaction of ATRIP and RPA. Then TopBP1 is
recruited to RPA-coated ssDNA by interacting with ATR-ATRIP, followed
by activation of ATR. Activated ATR phosphorylates Chk1.
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Phosphorylation of threonine (Thr)-1989 on ATR is a marker of ATR activation,
and this phosphorylation is DNA damage regulated. However, non-phosphorylatable
ATR protein mutant (T1989A) still can enable cells with DNA damage-induced ATR
checkpoint signaling pathway (Nam et al. 2011). It was reported that ATR activation
relies on RPA, ATRIP, and ATR kinase activity (Liu et al. 2012).

ATR Is Essential for Cell Viability
In contrast to ATM, ATR is essential for the viability of human and mouse cells.
Mouse model studies have shown that ATR knockout causes early embryonic lethality
(Brown and Baltimore 2000; De Klein et al. 2000; O’Driscoll 2009). An array of studies
has shown that ATR inhibition decreases carcinogenesis. Caffeine, an inhibitor of ATR,
has been shown to be an inhibitor of several cellular processes, including activation of
ATM and ATR (Sarkaria et al. 1999). It was reported that there is a link between
caffeinated beverage intake and significant decreases in several types of cancer, including
highly prevalent UV-associated skin carcinomas (Heffernan et al. 2009; Kawasumi et al.
2011). It is known that UV irradiation-induced mild DNA damage initiates cell cycle
progression arrest and promotes DNA damage repair. If DNA damage is overwhelming,
apoptosis will be induced to eliminate the damaged cells. Additionally, ATR-Chk1
pathway inhibition promotes apoptosis after UV treatment in primary human keratinocyte
(Heffernan et al. 2009). Taken together, these findings indicate that ATR inhibition is an
effective target in cancer prevention (Weber and Ryan 2015).
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Cell Death Is a Critical Defense Mechanism

Cell death is a critical defense mechanism for maintaining homeostasis of an
organism and for its survival. In general, when cells experience stress high enough to
jeopardize homeostasis, cell death is initiated to selectively eliminate damaged cells for
the wellbeing of the organism. The fact that more than 50% of human cancers are p53
deficient demonstrates that cell death plays a pivotal role in suppressing tumorigenesis.
When cells undergo overwhelming stress, such as irreparable DNA damage, the p53
tumor suppressor activates one type of cell death, named apoptosis, through DNA
damage checkpoint pathways (Mihara et al. 2003; Zilfou et al. 2012). On the other hand,
abnormal cell death is the cause of many human diseases including cardiovascular,
infection/allergy, and immune system diseases (Favaloro et al. 2012; Matt and Hofmann
2016). Thus, a proper balance between cell death and survival is important for the
wellbeing of a multicellular organism.
What is the standard to determine the death of a cell? The Nomenclature
Committee on Cell Death (NCCD) suggests that a cell should be considered dead when it
has gone through any one of the following molecular or morphological situations: ① the
loss of the integrity of the cellular plasma membrane; ② the complete fragmentation of
the cellular nucleus into discrete bodies; ③ the engulfment of the cellular corpse (or
cellular fragments) by an adjacent cell in vivo (Kroemer et al. 2009; Alvarez et al. 2010).
The catalogs of cell death have relied on morphological features before
considering biochemical or molecular biological tests that are available for assessing cell
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demise. In 1973, Schweichel and Merker proposed three types of cell death modalities.
The first type is “Type I cell death” associated with heterophagy, the second type is
“Type II cell death” associated with autophagy, and the last type is “type III cell death”,
which was not associated with any type of digestion. These three types of cell death
correspond to apoptosis, autophagy, and necrosis, respectively (Anon n.d.; Galluzzi et al.
2007; Kroemer et al. 2009). The morphological appearance of these three types of cell
death is shown in Figure 3.

Figure 3: Three types of cell death (modified from Escobar-Sánchez et al. 2015). (a)
Necrosis is characterized as cell swelling, plasma membrane rupture. (b) Apoptosis. Cell
shrinkage and formation of apoptotic bodies characterizes apoptosis. (c) Autophagic cell
death. Formation of autophagosome, which are characterized as typical double membrane,
indicating autolysis has occurred. Cell organelle disruption.
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Necrotic Cell Death

Necrosis Is a Controlled Cell Death
Necrotic cell death was traditionally thought to be an accidental and uncontrolled
cell death pathway resulting from cellular infection or physicochemical stress, such as
mechanical force, heat or cold. The morphology of necrotic cell death is characterized by
cytoplasmic swelling, irreversible and rapid loss of plasma membrane integrity, and
spillage of the intracellular components (Proskuryakov et al. 2003; Festjens et al. 2006;
Krysko et al. 2008) (Figure 4).

Figure 4: Morphology of necrosis and apoptosis (modified from Carella 2003). (a)
Necrosis is characterized as cell swelling, plasma membrane rupture. (b) Apoptosis. Cell
shrinkage and formation of apoptotic bodies characterizes apoptosis.

A growing body of evidence has indicated that necrotic cell death also plays an
important role in the maintenance of the physiologic condition of the cell. For example,
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necrosis may serve to maintain tissue and organism integrity by initiating inflammatory
responses in the host. High mobility group box 1 (HMGB1) protein is a nuclear protein
that is released from necrotic cells and acts as a signaling molecule to inform neighboring
cells that tissue repair is required (Harris and Andersson 2004; Zong and Thompson 2006;
Han et al. 2008; Cho et al. 2010). Further research has shown that necrotic cell death
occurs during many human pathological diseases (shown in Table1). All these suggest
that necrosis is a type of programmed cell death.
Table1: Pathologies associated with necrotic cell death (modified
from Proskuryakov et al. 2003; Conrad et al. 2016)
Pathology
Cells
Alzheimer disease

Neurons

Inflammatory diseases

Islet cells

Infection

Lymphocytes
Hepatocytes
Neutrophils
Macrophages

Ischemia

Various cells (myocardial cells, endothelial
cells, neurons et al.)

Since much of the knowledge about necrosis is still lacking, more studies on the
molecular mechanisms of necrotic cell death are necessary. A mechanistic understanding
of necrosis is important for drug development for human diseases related to necrosis.
Recently, necrosis has become a major interest in disease research and cancer therapy.
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ATP Depletion Is a Hallmark Event of Necrosis, which Is Poly(ADP-Ribose)
Polymerase1 (PARP1) Related
Unlike apoptosis, which is energy dependent, necrosis is characterized by
bioenergetic catastrophe. The collapse or failure of energy (adenosine triphosphate, ATP)
production in cells is a hallmark event of necrosis. Thus, any mechanisms by which ATP
is depleted could be linked to necrosis. Cellular stress resulting from nutrient starvation
or a reduced oxygen supply often results in ATP depletion. In solid tumors, necrosis is
commonly found in the internal region where insufficient vascularization causes oxygen
and glucose depletion (Zong and Thompson 2006).
Poly(ADP-ribose) polymerase (PARP) protein family comprises 17 members and
the primary function of this family of proteins is to generate adenosine diphosphate
ribose (ADPR) modifications on target proteins using nicotinamide adenine dinucleotide
(NAD+) as a substrate (Figure 5).

Figure 5: Structure of NAD+ (modified from Curtin 2005). PARP cleaves NAD+
and liberates ADPr and nicotinamide (NAM) (red), and ADPr can be polymerized via
linear or branched attachment points to the 2’-hydroxyl of the ribose.
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There are two types of ADPr modification, one is poly(ADPr) (PAR)
modification and the other is mono(ADPr) (MAR) modification. MAR modification is
when only one ADPr is covalently bound to the modification site(s) of a target protein.
PAR polymers are synthesized by covalently binding of ADPrs through linear or
branched attachment points (Kawaichi et al. 1981; Amé et al. 2004; Li and Chen 2014;
Curin 2005) (Figure 5). The ADPr modification function of each PARP family protein is
summarized in Table 2.
Table2: Summary of PARP enzymatic activities (modified from Vyas 2014)
Activity
PAR
MAR
PARP

1

2

5a

5b

3

4

6

7

8

10 11 12 14 15 16

Inactive
9

13

When PARP1 is activated, it can hydrolyze NAD+ into nicotinamide (NAM) and
ADPR (Figure 5). PARP1 covalently binds ADPR to a carboxyl group on itself or its
substrates through hydrogen bound. ADPRs are covalently bound together to form PAR
polymers (Figure 6). Decades ago, auto-PARylation of rat liver PARP1 showed that the
enzyme-bound polymers formed branch structures at a frequency of one in every 50
ADPR units. There were as many as 15 ADPR polymers on each enzyme (Modification
et al. 1981). PARP1’s ability to add PAR polymers onto itself or its substrates is termed
PARylation activity (Figure 6).
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Figure 6: PARylation activity of PARP1 (modified from Fischer et al. 2014). The NAD+
is hydrolyzed into NAM and ADPR, and ADPRs are covalently connected to a carboxyl
group of itself or its substrates to form PAR polymers.

PARP1 hyper-activation was demonstrated to be a cause of necrotic cell death by
leading to ATP depletion (Ha and Snyder 1999; Zong et al. 2004; Park et al. 2015)
(Figure 5). PARP1 is responsible for producing up to 90 % of PAR levels within cells
(D’Amours et al. 1999; Bürkle 2005; Yelamos et al. 2011). PARP1 plays a crucial role in
many cellular physiological and pathological processes, including DNA repair and cell
death. PARP1 is located in the nucleus, can be activated by genomic stress, and
physiologically participates in DNA repair (Dantzer et al. 2006; Poirier 2012). Hyperactivation of PARP1 has been shown to cause the excessive consumption of NAD+ in
cells, which results in glycolytic activity blockage. This leads to the fall in ATP and the
accumulation of phosphorylated sugars (Ying et al. 2003). Furthermore, the depletion of
NAD+/ATP pool leads to necrosis due to the metabolic collapse (Figure 7). Also,
oxidative stress-induced hyper-activation of PARP1 causes excessive NAD+ consumption
and consequently ATP depletion, leading into cell necrosis (Sriram et al. 2016).
26

Figure 7: Hyper-activation of PARP1 leads to necrosis via ATP depletion (modified from
Ström and Helleday 2012). Hyper-activation of PARP1 causes excessive consumption of
NAD+/ATP pool. At extremely low levels of ATP, the cell rapidly dies through necrosis
as a result of acute energy depletion.

Necrosis Is Independent of Cleavage of Caspase 3, Caspase 7 And PARP1
When cells go through apoptotic cell death, an early transient burst of PAR
modification of nuclear proteins by PARP1 is required. However, before the depletion of
the NAD+/ATP pool, PARP1 is inactivated by cleavage catalyzed by caspase 3,
generating a 24 kDa DNA-binding domain (DBD) and another 89 kDa catalytic fragment
(Kaufmann et al. 1993; Boulares et al. 1999; D’Amours et al. 2001). The cleavage of
PARP1 in cells going through apoptosis is not alone, the cleavage of caspase 3 and
caspase 7 is required for the activation of caspase 3 and caspase 7. In contrast to
apoptosis, necrotic cell death is independent of cleavage of caspase 3, caspase 7 and
PARP1 (Lazebnik et al. 1994; Ha and Snyder 1999; Kitanaka and Kuchino 1999; Bröker
et al. 2005).
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Necrosis as a Programmed Cell Death via Hyper-Activation of PARP1-Induced ATP
Depletion
Although necrotic cell death has been traditionally considered as a passive and
uncontrolled progress, more evidence has emerged to support the concept that necrosis
also may occur in an actively programmed manner (Proskuryakov et al. 2003; Festjens et
al. 2006; Zong and Thompson 2006; Alvarez et al. 2010; Kung et al. 2011; ChavezValdez et al. 2012; Ouyang et al. 2012; Vanden Berghe et al. 2014; Conrad et al. 2016).
For example, parthanatos, one form of necrosis, is believed to be a form of regulated
necrosis. It is characterized by hyper-activation of nuclear protein PARP1 by an array of
stimuli, such as DNA damage and reactive oxygen species (ROS) (Conrad et al. 2016;
Virág et al. 2013) (Figure 8). DNA damage initiates parthanatos via production of PARmodified apoptosis inducing factor (AIF) (Figure 8, number 1 process). Translocation of
AIF from mitochondria to the nucleus induces chromatin degradation (Figure 8, number
2 process). Large scale DNA fragmentation causes necrotic cell death. Last but not least,
PARP1 is hyper-activated during the regulated necrotic cell death (Figure 8).
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Figure 8. DNA damage-induced parthanatos (modified from Conrad et al. 2016). DNA
damage inducer/reagent initiates the hyper-activation of PARP1 in nucleus and the PAR
modification of AIF at mitochondria. AIF translocated from mitochondria to the nucleus
induces the degradation of chromatin to produce large scale DNA fragmentation
following by necrotic cell death.

Ca2+ May Be a Mediator of Necrosis via Hyper-Activation of PARP1
Bentle et al. reported in 2006 that when cells undergo stress of ROS and DNA
breaks, necrotic cell death was induced through Ca2+-dependent PARP1 hyper-activation
(Bentle et al. 2006). Later, several reports demonstrated that Ca2+ is a mediator of
necrotic cell death and may be responsible for the hyper-activation of PARP1-mediated
necrosis via NAD+/ATP pool depletion in cells (Yang et al. 2007; Francis et al. 2013;
Douglas and Baines 2014; Zhang et al. 2014). Nonetheless, the molecular mechanism
leading to necrosis remains elusive.
Under physiological conditions, cells maintain a cytosolic free- Ca2+
concentration of roughly 100 nM in contrast to ~1.2 mM extracellular concentration; a
spike of cytosolic Ca2+ to 200-400 nM due to release from the endoplasmic reticulum
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(ER), for example, can induce apoptosis; in contrast, a cytosolic concentration of Ca2+
higher than 1 μM resulting from influx across the plasma membrane triggers necrosis
(McConkey and Orrenius 1996; Zong and Thompson 2006). For example, Ca2+ overload
is a critical step of hydrogen peroxide (H2O2)-induced necrotic cell death. The
morphology of dying cells are featured with their plasma membrane swelling and loss of
the integrity of the plasma membrane. H2O2 treatment induces massive Ca2+ influx and
intracellular Ca2+ levels were measured to be a maximum concentration of 1200 nM.
Interestingly, the Ca2+ channel inhibitor cobalt was able to blunt this Ca2+ influx, blocked
necrosis and rescued the cells from H2O2–induced death (Li et al. 2010). Additional
research demonstrated that deregulation of mitochondrial activity is the consequence of
Ca2+ influx in cells. The decreased mitochondrial activity lead to increased ROS levels
and dramatically reduced levels of ATP. This resulted in the induction of necrotic cell
death in the cells (Zong and Thompson 2006; Kennedy et al. 2009).
How necrosis is regulated in cells remains largely unknown, particularly the
mechanism of Ca2+ overload-induced necrosis. Necrosis induced by Ca2+ overload
contributes to diseases such as heart failure, ischemic stroke, brain injury and immune
diseases (Kristián and Siesjö 1998; Nakayama et al. 2007; Monassier 2008; Kalogeris et
al. 2012). It is of utmost importance to investigate the biochemical and molecularmechanisms behind Ca2+ overload-induced necrotic cell death.

Human PARP1 protein
Human PARP1 protein includes three domains: ① a N-terminal zinc finger DBD,
including three zinc finger domains FI, FII and FIII (Figure 9), which contribute to
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binding to a variety of DNA structures such as single- and double-strand breaks,
crossovers, some specific double-stranded sequences (Kim et al. 2005), as well as a
nuclear localization signal (NLS) domain, ② a central auto-modification domain
containing a BRCA1 C terminus (BRCT) fold and linker regions that contain major sites
targeted for PARP1 auto-modification. The WGR domain participates in DNA binding,
and ③ a C-terminal catalytic domain containing two subdomains: a helical domain (HD)
that is conserved in DNA damage-dependent PARPs 1, 2, and 3, and the ADPribosyltransferase (ART) domain that contains the active site and a fold that is conserved
in all PARP family members ( Kim et al. 2005; Tao et al. 2009; Eustermann et al. 2011;
Dawicki-McKenna et al. 2015).

Figure 9: Schematic diagram of human PARP1 domains (modified from Yelamos et al.
2011; Dawicki-McKenna et al. 2015). The depiction of human PARP1 shows the relative
sizes and locations of DNA binding domain, auto-modification domain and catalytic
domain.

Glutamic Acid 988 Is Essential for the PARylation Activity of PARP1
Marsischky et al. demonstrated that glutamic acid (E) 988 of PARP1 is essential
for the synthesis (especially the elongation) of enzyme-linked PAR polymers. E988 is
located in the C-terminal catalytic domain of PARP1 (Marsischky et al. 1995). Mutated
PARP1 protein was produced by mutagenesis of E988 to glutamine (Q) or Alanine (A). It
was shown that mutated PARP1 is devoid of elongation activity (2800-fold reduction)
(Rolli et al. 1997).
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Aim of the Study
Cell death plays a critical defense role in maintaining homeostasis of an organism
and for its survival. A proper balance between cell death and survival is important for the
wellbeing of a multicellular organism. There are three major types of cell death,
apoptosis, autophagic cell death and necrosis. Unlike apoptosis and autophagic cell death
which are programmed cell death, necrosis has traditionally been considered as passive
and uncontrolled cell death. But recently, more and more evidence has been reported to
support the concept that necrosis is a regulated process.
PARP1 was demonstrated as a mediator of necrosis via hydrolyzing NAD+ to
produce PAR polymers on target proteins or itself. Hyper-activation of PARP1 leads to
necrotic death due to cellular metabolic collapse resulting from excessive consumption of
NAD pool (Ha and Snyder 1999; Zong et al. 2004; Park et al. 2015). And it was reported
that Ca2+ overload resulting from influx across the plasma membrane triggers necrosis
(McConkey and Orrenius 1996; Zong and Thompson 2006). However, much still remains
unknown about how necrosis is regulated in cells.
ATR, a PI3K family member, is best known for its regulatory role in DDR. Upon
genomic stress, it senses the cellular stress and works as a checkpoint kinase to
phosphorylate hundreds of its substrates, such as p53 and Chk1 (Figure 1). ATR/p53
checkpoint signaling pathways play a decisive role in determining cell fate (growth arrest
or apoptosis) (Wu et al. 2006; Vousden and Lane 2007; Wu et al. 2007; Shell et al. 2009;
Zhang et al. 2009; Li et al. 2011; Zilfou et al. 2012; Kracikova et al. 2013; Li et al. 2013;
Serrano et al. 2013; Hilton et al. 2015). Given the important role of ATR in regulating
cellular responses to genomic stress, we asked the question of whether ATR also could be
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a regulator of necrosis. Indeed, our data showed that cells treated with ionomycin had a
much higher rate of necrotic cell death in the absence of ATR than in the presence of
ATR. Five hypotheses were proposed as follows:
1.

ATR plays a role in NDDR wherein it is able to suppress ionomycin-

induced necrosis due to Ca2+ overload.
2.

Ionomycin treatment hyper-activates the poly(ADP-ribosyl)ation

(PARylation) activity of PARP1.
3.

Ionomycin treatment induces physical interaction of ATR and PARP1 for

suppressing necrosis.
4.

The anti-necrosis function of ATR depends on its kinase activity.

5.

Ca2+ itself hyper-activates the PARylation activity of PARP1 and primes

PARP1 for ATR binding.
Research shows that necrotic cell death happens during many human pathological
diseases (Table 1). Our ongoing studies will help to define the molecular mechanisms of
the anti-necrotic cell death activities of ATR relevant to human diseases.
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CHAPTER 2
MATERIALS AND METHODS

Materials

The materials that are listed below have been used for the research during Ph.D. study:
Table 3: General laboratory reagents, chemicals
Name
Manufacturer
1kb DNA ladder, GeneRuler
ThermoFisher Scientific
2-Mercaptoethanol (2-ME)
Sigma-Aldrich
30% acrylamide/bis Solution 29:1
Bio-Rad
6 X DNA loading dye
ThermoFisher Scientific
Acrylamide
Bio-Rad
Agar (Miller’s LB)
IBI Scientific
Agarose
ThermoFisher Scientific
Ampicillin
Research Products International Corp.
Bromophenol blue
Sigma-Aldrich
Bovine serum albumin (BSA)
Millipore
Butanol
EMD Millipore
Calcium chloride (CaCl2)
Sigma-Aldrich
Dimethyl sulfoxide (DMSO)
ThermoFisher Scientific
Dithiothreitol (DTT)
Research Products International Corp.
Dulbecco’s modified eagle medium
HyCloneTM Liquid Tissue Culture Media,
(DMEM) with phenol red, 4500 mg/L
GE Healthcare Life Sciences
glucose, 4.0 mM L-glutamine, and 110
mg/L sodium pyruvate
Ethanol (EtOH; molecular grade)
Pharmaco-AAPER
Ethidium bromide (EB)
ThermoFisher Scientific
Fetal bovine serum (FBS)
GE Healthcare Life Sciences
Formaldehyde, 16%
Electron Microscopy Sciences
Gentle ReviewTM Stripping Buffer
Amresco® Biochemicals and Life Science
Research Products
Glycerol
J.T.Baker
HEPES
EM Science
Hydrochloric acid (HCl)
ThermoFisher Scientific
Hygromycin B
ENZO Life Sciences
Ionomycin (calcium salt)
Cayman Chemical
Isopropanol
ThermoFisher Scientific
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Table 3 (continued)
Isopropyl-β-D-thiogalactopyranoside
(IPTG)
jetPEITM HTS DNA transfection Reagent
Methanol (MeOH)
Microscope slides 25X75X1 mm
Milk powder, non-fat
McCoy’s 5A, HyClone Classical Liquid
Media
Monopotassium phosphate (KH2PO4)
Multiwell dishes: 6-well, 12-well, 24-well
and 96-well
Neomycin sulfate solution
Nicotinamide adenine dinucleotide (NAD,
[32P])
Penicillin-streptomycin
Petri dishes: 35mm, 60mm, 70mm,
100mm and 150mm diameter
Phosphatase inhibitor
Pierce® 660 nm Protein Assay Reagent
PierceTM Protein G Plus Agarose Beads
Potassium chloride (KCl)
Precision Plus ProteinTM Unstained
Standards
Propidium iodide (PI)
Protease inhibitor
Halt Protease and Phosphatase Inhibitor
Cocktail
PureProteome Protein G Magnetic Beads
Puromycin • 2HCl
Sodium dodecyl sulfate (SDS)
Sodium chloride (NaCl)
Sodium phosphate dibasic (Na2HPO4)
Tetramethylethylenediamine (TEMED)
Tris-Acetate 3-8% gradient
polyacrylamide gels, NuPAGE
TRIS base
Triton X-100
Trypan blue solution, 0.4 % (w/v)
Trypsin-Versene Mixture
Tryptone
Tween 20
Yeast extracts

Research Products International
Polyplus-transfection
BDH
Fisher Scientific
Food Club
GE Healthcare Life Sciences
Fisher
Cyto-One
Scientific Sales, Inc
Perkin Elmer
Hyclone
VWR
GBiosciences
ThermoFisher Scientific
ThermoFisher Scientific
ThermoFisher Scientific
Bio-Rad
Sigma-Aldrich
ThermoFisher Scientific
ThermoFisher Scientific
EMD Millipore
Enzo Life Sciences
Amresco
EMD
ThermoFisher Scientific
ThermoFisher Scientific
ThermoFisher Scientific/Life
Technologies
Sigma-Aldrich
Sigma-Aldrich
Corning
Lonza
Lonza
Amresco
ThermoFisher Scientific
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Luria broth (LB) medium:
10 g/L tryptone
5 g/L yeast extract
10 g/L NaCl
pH 7.5
LB agar medium for LB plate:
LB medium with 15 g/L agar
Antibiotic concentration in either LB medium or LB agar plate:
100 μg/mL ampicillin, was used for selective growth of ampicillin-resistant
plasmid-transformed E.coli bacteria

50 X TAE electrophoresis running buffer, 1L:
242 g Tris base
57.1 mL glacial acetic acid
100 mL 0.5 M EDTA
Whole cell lysis buffer:
150 mM NaCl
50 mM Tris-HCl pH 8.0
1 % Triton X-100
1 mM EDTA
Protease and Phosphatase Inhibitors were added fresh before use.
PBS (10X, 1L):
80 g NaCl
20 g KCl
14.4 g Na2HPO4
2.4 g KH2PO4
pH was adjusted to 7.4 via pH meter
ddH2O was added to 1 L. Autoclaved to sterilize.
Final (1X) working concentration:
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140 mM NaCl, 27 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4.
2 X SDS gel-loading buffer:
100 mM Tris-HCl, pH 6.8
200 mM DTT (dithiothreitol)
4 % SDS (sodium dodecyl sulfate, electrophoresis grade)
0.2 % bromophenol blue
20 % glycerol
Tris-glycine electrophoresis buffer (5X, 1L):
15.1 g Tris base
94 g glycine
5 g SDS
Added ddH2O to 1 L
Final (1X) working concentration: 25 mM Tris, 250 mM glycine, 0.1 % SDS.
Transfer Buffer (1L):
5.8 g Tris base
2.9 g glycine
0.37 g SDS
100 mL methanol
Added ddH2O to 1L
Final working concentration: 48 mM Tris, 39 mM glycine, 0.037 % SDS, 10 % methanol.

Table 4: Enzymes for DNA manipulation
Name
Alkaline phosphatase, calf intestinal (CIP)
FastDigest NdeI
FastDigest XhoI
LongAmp Taq DNA Polymerase
T4 DNA Ligase

Manufacturer
New England BioLabs
ThermoFisher Scientific
ThermoFisher Scientific
New England BioLabs
New England BioLabs
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Table 5: Antibodies
Name, Catalog Number, Host
Anti-actin
Anti-ATR, A300-137A, rabbit
Anti-ATR, A300-138A, rabbit
Anti-ATR (phosphor Ser428), 2853,
rabbit
Anti-ATR (phosphor Thr1989),
GTX128145, rabbit
Anti-ATRIP, A300-670A, rabbit
Anti-Chk1, 2360, mouse
Anti-Chk1 (phosphor Ser245), 2348,
rabbit
Anti-Cyclophilin A, rabbit
Anti-Cyclophilin D, AP1035, mouse
Anti-FLAG M2, F3165, mouse
Anti-GAPDH, rabbit
Anti-γH2AX, rabbit
Anti-Histone H1, GTX87506, rabbit
Anti-Histone H3, rabbit
Anti-HMGB1, GTX101277, rabbit
Anti-Myc-Tag, 2276, mouse
Anti-p53 (phosphor Ser15), rabbit
Anti-PAR, 4335-MC-100, mouse
Anti-PARP1, 9532, rabbit
Anti-PARP1, 9542, rabbit
Anti-PARP1, sc-8007, mouse
Anti-PARP1-T368, rabbit
Anti-Pin1, 07-091, rabbit
Anti-Pin1, GTX113245, rabbit
Anti-Rabbit, 31460, goat
Anti-Goat, sc-2020, donkey
Anti-Mouse, 31160, goat
Anti-Mouse, sc-2005, goat

Manufacturer
EMD Millipore
Bethyl Laboratories
Bethyl Laboratories
Cell Signaling Technology
GeneTex
Bethyl Laboratories
Cell Signaling Technology
Cell Signaling Technology
GeneTex
EMD Millipore
Sigma-Aldrich
Cell Signaling
Bethyl Laboratories
GeneTex
Santa Cruz Biotechnology
GeneTex
Cell Signaling Technology
Cell Signaling Technology
Trevigen
Cell Signaling Technology
Cell Signaling Technology
Santa Cruz biotechnology
OAAB
EMD Millipore
GeneTex
ThermoFisher Scientific
Santa Cruz Biotechnology
ThermoFisher Scientific
Santa Cruz Biotechnology
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Table 6: Mammalian cell lines and cultural media
Cell Line
Culture Media
A549, ATCC
DMEM + 10% FBS + 1% P/S
A549 shCTRL & shPARP1 (From Dr.
DMEM + 10% FBS + 1% P/S + 1.5 μg/ml
Csaba Szabo, University of Texas
puromycin
Medical Branch)
HCT116 ATR+/+
McCoy’s 5A + 10% FBS + 1% P/S
flox/HCT116 ATR
McCoy’s 5A + 10% FBS + 1% P/S
HEK293T, ATCC
DMEM + 10% FBS + 1% P/S
SHSY-5Y (From Dr. Meng-Yang Zhu,
DMEM + 10% FBS + 1% P/S
East Tennessee State University, Quillen
College of Medicine)
U2OS ATR-WT & ATR-KD (From Dr.
DMEM + 10% FBS + 1% P/S + 0.2
Paul Nghiem, University of Washington
mg/ml Neomycin + 0.2 mg/ml
Medical Center)
hygromycin, (Doxycycline [5 μg/ml, 24
hrs] for inducing recombinant ATR-WT
protein expression)

Table 7: Commercial kits
Name
Biotin Chromogenic Detection Kit
CytoTox 96® Non-Radioactive
Cytotoxicity Assay
Cytoplasmic and Nuclear Protein
Extraction Kit, ProteoJETTM
EZNA® Plasmid DNA Midi Kit I
EZNA® Plasmid DNA Mini Kit I
In-Fusion HD Cloning Kit
NucleoSpin® Gel and PCR Clean-up
QIAquick® Gel Extraction Kit
SuperSignal® West Pico
chemiluminescent Substrate Kit

Manufacturer
ThermoFisher Scientific
Promega
Fermentas Life Sciences
Omerga
Omerga
Clontech Laboratories
TaKaRa Clontech
Qiagen
ThermoFisher Scientific
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Methods

Preparation of Competent E.coli Bacterial Cells
A sterile loop was used to streak the E.coli, either DH5α or BL21 (DE3), on a LB
agar plate. The E.coli was from frozen glycerol stock in a sterile cryogenic storage vial at
-80°C freezer. The LB agar plate was put in 37°C incubator overnight. Next day, a
colony was picked up from the LB agar plate by using a sterile 10 μL micropipette tip or
toothpick. Dropped the tip or toothpick into a 14 mL polypropylene Falcon tube
containing 2 mL LB medium. Incubated bacterial culture overnight at 37°C in a shaking
incubator with 200 rpm. Next day, the cloudy haze culture medium indicated the growth
of bacteria and the OD600 of the culture medium is around 1.5. Transferred 200 μL of the
bacterial culture into a 30 mL LB broth in a sterile conical culture flask. Incubated around
2.5 hrs at 37°C in a shaking incubator with 200 rpm until the OD600 reach around 0.2.
Transferred the bacterial culture into a 50 mL sterile centrifuge tube and place it on ice
for 10 mins followed by centrifugation at 2500 rpm for 10 mins at 4°C. Removed the
supernatant and gently re-suspended the bacteria pellet with 25 mL 100 mM sterile CaCl2.
Incubated the centrifuge tube containing the re-suspended bacteria on ice for 20 mins
followed by centrifugation at 2500 rpm for 10 mins at 4°C. Removed the supernatant and
gently re-suspended the bacteria pellet with 1 mL 100 mM sterile CaCl2. Incubated the
centrifuge tube on ice for 30 mins. 200 μL of 80 % sterile glycerol was added into the
centrifuge tube and gently mixed it with re-suspended bacteria. Aliquoted 100 μL of
mixed bacteria into each 1.5 mL micro-centrifuge tube and snap-frozen in liquid nitrogen.
Stored the aliquots in -80°C ultralow temperature freezer.
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Bacterial Transformation with Plasmid
E.coli competent cells (either DH5α or BL21 (DE3) bacterial cells) is removed
from -80°C freezer and thawed on ice just before use. LB agar plates (containing
appropriate antibiotic) are taken out from 4°C and let them warm up in 37°C incubator.
Set the temperature of the water bath at 42°C. Mix 1 to 5 μL of DNA plasmid (usually 1
ng to 100 ng) into 50-100 μL of competent cells in a 15 mL micro-centrifuge. Gently
mixed to ensure even distribution. Placed the tubes containing the competent cells/DNA
mix on ice for 30 min. Heat shock each transformation tube in the 42°C water bath for 45
sec. Placed the tubes back on ice for 1-2 min. Add 400-450 μL 37°C warmed LB medium
to bring the final volume to 500 μL. Incubated by shaking at 200 rpm for 1 hr at 37°C.
Plated some or all of the transformation onto each 10 cm LB agar plate containing the
appropriate antibiotic. Plates were incubated at 37°C for 17-19 hrs.
cDNA Subcloning by Polymerase Chain Reaction (PCR) and Restriction Enzyme
Digestion
ATR complementary DNA (cDNA) fragment corresponding to its protein
fragment (A359-N484) (ATRf) was needed to insert the pTBY2 vector (Result “ATR
cDNA fragment (A359-N484, ATRf) subclone” section and is shown in Figure 22).
The purpose of the primer design for amplification of ATR cDNA fragment
(A359-N484) (ATRf) is to ① amplify the ATR cDNA fragment corresponding to its
protein fragment A359-N484 from ATR cDNA template, ② add 6 X His tag at the Nterminal of ATR cDNA fragment, ③ create two recognition sites for restriction enzymes
(NdeI and XhoI) on the PCR amplified ATR cDNA fragment with 6 X His tag at its Nterminal. Two primers are:
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ATRfA359-NdeI-F: 5’TGAGGTCATATGCATCACCATCACCATCACGCTGGGTATGAATCTGCT-3’ and
ATRfN484-XhoI-R: 5’-GGTGGTCTCGAGATTCTTTAGGCCACTGTATTCAAGG-3’.
NdeI restriction enzyme’s recognition site is CATATG (underline), while XhoI
restriction enzyme’s recognition site is CTCGAG (underline). 6 random oligonucleotides
were added at the very 5’ end of each primer’s recognition site to make sure of the
cleavage efficiency of each enzyme is > 90 %. Oligonucleotides of 6 X His tag
(CATCACCATCACCATCAC, italicized) is added after the 3’ end of NdeI enzyme’s
recognition site, so the ATR cDNA fragment (A359-N484) is 6 X His tagged.
ATR cDNA fragment (A359-N484) PCR reaction mix was prepared as follows (50 μL
PCR mix per reaction):
ddH2O

31.5 μL

5 X LongAmp Taq reaction buffer

10 μL

10 mM dNTPs

1.5 μL

10 μM Forward Primer (ATRfA359-NdeI-F)

2 μL

10 μM Reverse Primer (ATRfN484-XhoI-R)

2 μL

ATR cDNA template plasmid (pcDNA3.1-FLAG-ATR) 1 ng/μL

1 μL

LongAmp Taq DNA polymerase (0.1 U/μL)

2 μL

Thermo-cycled with the following condition:
94°C
30 cycles
65°C

5 min
94°C

30 sec

50°C

60 sec

65°C

20 sec (50 sec/kb of plasmid length)

10 min

Hold at 4°C
5 μL of 50 μL PCR product was loaded on a 1.5 % agarose gel. The PCR
product’s size should be around 400 base pair (bp). The other 45 μL PCR product was
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cleaned up by NucleoSpin® Gel and PCR Clean-up kit. Both the PCR products and vector
of pTYB2 plasmid were double digested by NdeI and XhoI. The double digestion
reaction was as follows:
PCR product double digestion (30 μL of mix per reaction):
ddH2O:

15 μL

10 X restriction enzyme digestion buffer

3 μL

PCR of ATR fragment (A359-N484) 100 ng/μL

10 μL

NdeI (10 U/μL)

1 μL

XhoI (10 U/μL)

1 μL

pTYB2 vector plasmid-double-digestion (20 μL of mix per reaction):
ddH2O:

5 μL

10 X restriction enzyme digestion buffer

2μL

pTYB2 vector plasmid (400 ng/μL)

10 μL

NdeI (10 U/μL)

1 μL

XhoI (10 U/μL)

1 μL

Alkaline Phosphatase (CIP) (10 U/μL)

1 μL

Both reactions were incubated in PCR tubes in the thermos-cycler at 37°C for 1 hr.
Double-digested PCR product (ATR fragment) and double-digested pTYB2
vector plasmid were cleaned up by using NucleoSpin® Gel and PCR Clean-up kit to get
rid of salt.
Ligation of double-digested pTYB2 and PCR product of ATR cDNA fragment
(A359-N484) as follows (20 μL mix per reaction):
ddH2O

5 μL

10 X T4 DNA ligase buffer

2 μL

Double-digested pTYB2 vector

6 μL

Double-digested ATR fragment (A359-N484)

6 μL

T4 DNA ligase (400 U/μL)

1 μL
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The molar ratio of double-digested pTYB2 vector to double-digested ATR
fragment is 9:1.
The reaction mix in a PCR tube was incubated in thermo-cycler at 16°C overnight
followed by heat inactivation of T4 DNA ligase at 65°C for 10 min.
5 μL of T4 DNA ligation reaction mixture was used to transform into competent
DH5α bacteria. Plated the transformed cells on an ampicillin LB agar plate and incubated
the plate at 37°C for 17-19 hrs.
Colony picking up and restriction-enzyme double digestion screen colony. A
sterile 10 μL pipette tip or toothpick was used to pick up one colony from the plate.
Dropped the tip or toothpick into a 50 mL Falcon tube containing 7.5 mL LB medium
with 100 ug/mL ampicillin. Four colonies were picked up randomly from the plate and
each colony was put in one 50 mL Falcon tube followed by incubating at 37°C overnight.
The plasmids were isolated from each 50 mL Falcon tube bacterial culture medium by
using EZNA® Plasmid DNA Mini Kit I. Each plasmid and vector pTYB2 plasmid was
double-digested with restrict enzymes NdeI and XhoI. The double-digestion-products
with PCR product of ATR cDNA fragment (A359-N484) and GeneRuler 1kb DNA
ladder maker were separated by agarose gel electrophoresis in different wells of a 1.2 %
agarose gel. If the small piece of the double-digestion products is the same size as the
PCR product of ATR cDNA fragment, the plasmid was considered as a candidate
plasmid pTYB2-ATR (A359-N484). Two candidate plasmids pTYB2-ATR (A359-N484)
was sent out for DNA sequencing by T7 universal primer.
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Plasmid Site-Directed Mutagenesis
Plasmid site-directed mutagenesis was generated by following the protocol of InFusion HD Cloning Kit from Clontech Laboratories.
The In-Fusion Enzyme from the kit fuses PCR-generated DNA sequences
efficiently and precisely by recognizing a 15 by overlap at their ends. The site-directed
mutagenesis sites are included in 15 bp overlap.
The PCR primers were designed as follows: ① Every In-Fusion primer must have
two characteristics: the 5’ end of the primer must contain 15 bases that are homologous to
15 bases at one end of the DNA fragment to which it will be joined. The 3’ end of the
primer must contain sequence that is specific to the target gene. ② The 3’ portion of
each primer should: be gene-specific; be between 18-25 bases in length, and have a GCcontent between 40-60 %; have a melting temperature (Tm) between 58-65°C and the Tm
difference between the forward and reverse primers should be ≤ 4°C.
PCR reaction mix was prepared as follows (25 μL PCR mix per reaction):
ddH2O

9.5 μL

5 μM Forward Primer

2 μL

5 μM Reverse Primer

2 μL

PARP1 cDNA Template Plasmid (pcDNA3.1-hygro-PARP1-Myc-6His) 1 ng/μL

1 μL

CloneAmp HiFi PCR Premix

12.5 μL

Thermo-cycled with the following condition:
35 cycles

98°C

10 sec

55°C

15 sec

72°C

42.5 sec (5 sec/kb of plasmid length)

Hold at 4°C
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Cloning Enhancer Treatment. The treatment is used to digest the PARP1 cDNA
template plasmid used in the PCR reaction to avoid the PARP1 wild type (WT) colonies
on the antibiotic selective LB agar plates. The cloning enhancer treatment reaction mix
was prepared as follows (7 μL per reaction):
PCR reaction mix

5 μL

Cloning Enhancer

2 μL

The reaction mix was incubated in a PCR thermal cycler at 37°C for 15 min
followed by 80°C for 15 min.
In-Fusion Cloning Procedure. The reaction mixture was prepared as follows (10
μL per reaction):
ddH2O

6 μL

Cloning Enhancer-treated fragments

2 μL

5 X In-Fusion HD Enzyme Premix

2 μL

The reaction mix was incubated in a PCR thermal cycler at 50°C for 15 min
followed by 4°C hold or put on ice.
5 μL of the In-Fusion Cloning Procedure mix was used for bacterial
transformation to 50 μL Stellar Competent Cells provided by the kit.
The LB-ampicillin agar plates covered with 100 µL of transformed bacteria were
placed in incubator at 37°C for 17-19 hrs. Next day, colonies were picked for plasmids
purification and agarose gel electrophoresis was employed to select the candidate sitedirected mutagenesis plasmids. If the site-directed mutagenesis plasmids were the same
size of wild type plasmid, they were sent out later for DNA sequencing with appropriate
sequencing primers.
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Table 8: List of plasmids
Plasmids that were used as the site-directed mutagenesis template
Mammalian expression plasmid pcDNA3.1-hygro-PARP1-Myc-6His (Gift from Dr.
Saraswati Sukumar)
Plasmids that were generated by site-directed mutagenesis
pcDNA3.1-hygro-PARP1-S179A-Myc-6His
pcDNA3.1-hygro-PARP1-T325A-Myc-6His
pcDNA3.1-hygro-PARP1-T368A-Myc-6His
pcDNA3.1-hygro-PARP1-S721A-Myc-6His
pcDNA3.1-hygro-PARP1-S727A-Myc-6His
pcDNA3.1-hygro-PARP1-S874A-Myc-6His
pcDNA3.1-hygro-PARP1-S911A-Myc-6His
pcDNA3.1-hygro-PARP1-E988K-Myc-6His
pcDNA3.1-hygro-PARP1-E988Q-Myc-6His
pcDNA3.1-hygro-PARP1-D968N-Myc-6His
pcDNA3.1-hygro-PARP1-D965N D968N-Myc-6His
pcDNA3.1-hygro-PARP1-∆CaBS-Myc-6His

Table 9: List of primers for site-directed plasmid mutagenesis and cDNA fragment
subcloning
Primers that were used for site-directed mutagenesis
PARP-1-S179A-F: 5’- GCGGCTCAGCTCAAGGGCTTCAGCCTCCTTGCTAC -3’
PARP-1-S179A-R: 5’- CTTGAGCTGAGCCGCACTGTACTCGGGCCGGAAAC-3’
PARP-1-T325A-F: 5’- GTC AAG GCA CAG ACA CCC AAC -3’
PARP-1-T325A-R: 5’ - TGT CTG TGC CTT GAC CAT ACA CTT G -3’
PARP1-T368A-F: 5'- GCCGCGCCTCCGCCCTCCACAGCCTCGGCTCCTGCT -3'
PARP1-T368A-R: 5'- GGGCGGAGGCGCGGCCGCCACGGAGGCGCTGGTT -3'
PARP-1-S721A-F:
5’- GCGGTGGCTCAGGGCAGCAGCGACTCTCAGATCCTGGAT -3’
PARP-1-S721A-R:
5’- GCCCTGAGCCACCGCCTGCTGGACCTCACTGAGGATGGA-3’
PARP-1-S727A-F: 5’- CGA CGC TCA GAT CCT GGA TCT -3’
PARP-1-S727A-R: 5’- AGG ATC TGA GCG TCG CTG CT -3’
PARP-1-S874A-F: 5’- GGA TCC TGG CTC AGG GTC TT -3’
PARP-1-S874A-R: 5’- CCT GAG CCA GGA TCC CAG CAA A -3’
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Table 9 (continued)
PARP-1-S911A-F: 5’- ACT GCC ATA CGG CTC AGG GAG A -3’
PARP-1-S911A-R: 5’- GAG CCG TAT GGC AGT AGT TGG C -3’
PARP1-E988K-F: 5’-TATAACAAGTACATTGTCTATGATATTGCTCAGG-3’
PARP1-E988K-R: 5’-AATGTACTTGTTATATAGTAGAGAGGTGTCATTC-3’
PARP1-E988Q-F: 5’-TATAACCAGTACATTGTCTATGATATTGCTCAGG-3’
PARP1-E988Q-R: 5’-AATGTACTGGTTATATAGTAGAGAGGTGTCATTC-3’
PARP1-D968N-F:
5’- CTGGATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’
PARP1-D968N-R: 5’GTTTACACCATCCAGACTAATGTTAGCTGAAGGATCAGGG -3’
PARP1-D965ND968N-F:
5’ - CTGAATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’
PARP1-D965ND968N-R:
5’- GTTTACACCATTCAGACTAATGTTAGCTGAAGGATCAGGG -3’
PARP1-∆CaBS-F:
5’- GGCAAAACTACCCCTGTTCCTCTTGGGACCGGGATTTC -3’
PARP1-∆CaBS-R:
5’- AGGGGTAGTTTTGCCCAAACCTTTGACACTGTGCTTGC -3’
PARP1-D968N-F:
5’- CTGGATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’
PARP1-D968N-R: 5’GTTTACACCATCCAGACTAATGTTAGCTGAAGGATCAGGG -3’
PARP1-D965ND968N-F:
5’ - CTGAATGGTGTAAACGTTCCTCTTGGGACCGGGATTTC -3’
PARP1-D965ND968N-R:
5’- GTTTACACCATTCAGACTAATGTTAGCTGAAGGATCAGGG -3’
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Table 10: List of primers for plasmid sequencing
DNA sequencing primers
Primer for sequencing pcDNA3.1-hygro-PARP1-S179A-Myc-6His and pcDNA3.1hygro-PARP1-T325A-Myc-6His:
PARP1-565-F: 5’-ATAGAAAAGGGCCAGGTGCG-3’
Primer for sequencing pcDNA3.1-hygro-PARP1-T368A-Myc-6His:
PARP1-1061-F: 5'- AATGCTCGGGTCAGCTGGTCT-3'
Primer for sequencing pcDNA3.1-hygro-PARP1-S721A-Myc-6His and pcDNA3.1hygro-PARP1-S727A-Myc-6His:
PARP1-2169-F: 5’-CAAGCCAGTTCAGGACCTCA-3’
Primer for sequencing pcDNA3.1-hygro-PARP1-S874 and pcDNA3.1-hygro-PARP1S911A-Myc-6His:
PARP1-2636-F: 5’-ATGCAACCACACACAATGCG-3’
Primer for sequencing pcDNA3.1-hygro-PARP1-D968N-Myc-6His, pcDNA3.1-hygroPARP1-D965ND968N-Myc-6His, pcDNA3.1-hygro-PARP1-∆CaBS-Myc-6His,
pcDNA3.1-hygro-PARP1-E988K-Myc-6His and pcDNA3.1-hygro-PARP1-E988QMyc-6His:
PARP1-3214-R: 5’-ACCACAGGGAGGTCTTAA-3’

Plasmid Transfection of Mammalian Cells
Transient Transfections:
jetPEI DNA transfection reagent was used and followed the DNA transient
transfection protocol for adherent cells. Briefly, for transfection in 24-well plates, cells
were seeded in the plates 24 hours prior to transfection. The number (variable of different
cell lines) of cells seeded enabled to 50-70 % confluency at the time of transfection next
day. Changed the media next day before performing the experiment and added 1 mL of
media per well. Per one well of 24-well plate, diluted 1 μg of DNA in 150 mM NaCl to a
final volume of 50 μL in one 1.5 mL micro-centrifuge tube. Vortexed gently (4000rpm
for 10 seconds) and spun down briefly to allow the liquid concentrating at the bottom of
the tube. Per well, diluted 2 μL of jetPEI reagent in 150 mM NaCl to a final volume of 50
μL in another 1.5 mL micro-centrifuge tube. Vortexed gently and spun down briefly.
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Added the 50 μL jetPEI solution to the 50 μL DNA solution all at once. Vortexed the
solution immediately and spun down briefly. Incubated for 15 to 30 min at room
temperature. Per well, added the 100 μL jetPEI/DNA mix drop-wise to the cells in 1 mL
of serum-containing medium and evenly mixed by gently swirling the plate. Returned the
plates to the cell culture incubator. 48 hours later, transfected cells are allowed for the
following planned experiment assays.
Stable Transfection:
The transfection was performed in 6-well plates, 60 mm or 100 mm dishes. The
protocol was modified from the jetPEI stable transfection protocol. Briefly, performed
the transient transfection as described above. Started antibiotic selection 48 hours after
transfection dependent on the antibiotic gene that plasmid contained. Maintained
antibiotic selection for 14 days by replacing the selective medium every 3 or 4 days.
Isolated large (500-1,000 cells), healthy colonies using sterile 10 μL micropipette tips or
toothpicks, and continued to maintain cultures in medium containing the appropriate
antibiotic. Transferred single cells from resistant colonies into the wells of 96-well plates
to confirm that they can yield antibiotic-resistant colonies.

siRNA-Directed Protein Knockdown in Cells
INTERFERin siRNA transfection reagent was used and followed the
INTERFERin siRNA transfection protocol for adherent cells. Briefly, for siRNA
transfection in 24-well plates, cells were seeded in each well of 24-well plates 24 hours
prior to transfection. The number (variable of different cell lines) of cells seeded enabled
to 30-50 % confluency at the time of transfection next day. Changed the media next day
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before performing the experiment and added 500 μL of media per well. Per well, 10 μM
of siRNA was diluted in 100 μL of serum-free medium in one 1.5 mL micro-centrifuge
tube. Vortexed gently (4000 rpm for 10 seconds) and spun down briefly to allow the
liquid concentrating at the bottom of the tube. Per well, added 3 μL of INTERFERin
reagent into siRNA solution. Vortexed gently, spun down and incubated 10 minutes at
room temperature. Per well, added transfection mix to the cells in serum containing
medium and gently swirling the plate for 10 seconds. Returned the plates to the cell
culture incubator. 72 hours later, transfected cells are allowed for the following planned
experiment assays.

Subcellular Fraction Preparation
Subcellular fractionation was performed using the ProteoJETTM cytoplasmic and
nuclear protein extraction kit (Fermentas) by following the protocol of the kit for
adherent cells. Briefly, cells were harvested by scraping or trypsinized from the bottom of
the dishes where cells go on. Cells were pelleted by centrifugation at 4°C with 10,000
relative centrifugal force (rcf) for 10 seconds. Estimated the packed cell volume. 10
volumes of cell lysis buffer (with protease inhibitors and DTT) were added to 1 volume
of packed cells. Pipetted up and down several times to suspend the cell pellet. Placed the
tube with cellular lysis suspension on ice for 10 minutes and flipped the bottom of the
tube several times after the tube was placed on ice for 5 minutes. Separated the
cytoplasmic fraction from nuclei by centrifugation at 500 X g for 7 minutes at 4°C.
Carefully remove the supernatant to a new tube pre-cooled on ice. Set the nuclear pellet
on ice. Cytoplasmic protein extract was cleared by centrifugation at 13,000 X rpm for 15
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min at 4°C. Transferred the supernatant to a new tube marked as cytoplasmic fraction
(CyF). Nuclei was washed twice as follows: adding 500 μL of the nuclei washing buffer
(with protease inhibitors and DTT) to nuclear pellet followed by pipetting up and down
several times; pelleted the nuclei by centrifugation at 500 X g for 7 minutes at 4°C and
discarded the supernatant. Added 10 volumes of ice-cold nuclei storage buffer (with
protease inhibitors and DTT) to the nuclear pellet. Pipetted up and down several times to
suspend the nuclear pellet. 1/10 volume of the nuclei lysis reagent was added to nuclei
suspension. Vortexed briefly and rotated for 15 minutes at 4°C (900-1200 rpm) followed
by placed on ice for 20 minutes.
Table 11: Volume of 0.1 M DTT added into each lysis buffer (0.1 M DTT was added to
the provided reagents fresh before use)
Buffer
Required Volume Per Prep. 0.1 M DTT
Cell Lysis Buffer

200 μL

2 μL

Nuclei Washing Buffer

1000 μL

30 μL

Nuclei Storage Buffer

150 μL

7.5 μL

Protein Concentration Measurement
Protein concentration was measured with Pierce 660 nm Protein Assay Reagent
by following the microplate procedure protocol of the reagent. Briefly, prepared the 50
ng/μL, 100 ng/μL, 200 ng/μL and 400 ng/μL standard by diluting 2,000 ng/μL BSA
standard with ddH2O. Pipetted 10 μL of each triplicate of standard and ddH2O into wells
of 96-well plate. Pipetted 2 μL of protein samples into wells of 96-well plate. Each
protein sample is triplicate. The corresponding buffer that protein samples dissolved in as
mock. Added 8 μL of ddH2O to each well containing 2 μL samples or buffer to ensure the
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total volume of each well was 10 μL. Added 150 μL of the protein assay reagent to each
well. Covered the plate and mixed on a plate shaker at medium speed for 1 minute.
Incubated at room temperature for 5 minutes. Measured the absorbance of the standards
and proteins samples at 660 nM. A standard curve was built by plotting the average
blank-corrected 660 nM measurement of each BSA standard with unit of ng/μL. Used the
standard curve to determine the protein concentration of each protein sample.

Immunodetection (Western Blot)
After the procedure of protein blotting, PVDF membrane was taken out and used
in an immunodetection procedure to reveal specific/expected proteins. Briefly, placed the
PVDF membrane into blocking solution (5% of non-fat milk in 1X Tris-buffered saline
tween-20 (TBST) buffer) on a rocker gently for 1 hour at room temperature or overnight
at 4°C. A sufficient volume of blocking buffer was used to keep the membrane fully
covered. Rinsed the membrane briefly in 1 X TBST buffer. Appropriately diluted primary
antibody in 1 X TBST buffer according to each antibody, usually from 1:100 to 1:3000.
Incubated the membrane with sufficient volume of primary antibody buffer to keep the
membrane fully covered on a rocker gently shaking. Incubated for 2 hours at room
temperature or overnight at 4°C. Rinsed the membrane in 1 X TBST buffer (3 X 10 min)
on a shaker gently in a sufficient volume to keep the membrane fully covered. Diluted
(1:5000) horseradish peroxidase (HRP)-conjugated secondary antibody in 1 X TBST
buffer. Incubated the membrane in a sufficient volume of the secondary antibody buffer
to keep the membrane well covered for 1 hour at room temperature on a rocker gently
shaking. Rinsed the membrane in 1 X TBST buffer (2 X 10 min) on a shaker gently
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shaking. Drained excess 1 X TBST buffer form the membrane and added appropriate
volume of HRP substrate solution (from SuperSignal® West Pico chemiluminescent
substrate kit) on the surface of the membrane. Incubated the membrane with the substrate
solution for 5 minute, kept the membrane from light. Removed the membrane from the
substrate solution and drained the excess reagent. Exposed the membrane to Fuji imagine
system.
20 X Tris-buffered saline (TBS) Buffer Stock (1L)
60 g Tris base
160 g NaCl
4 g KCL
Added ddH2O to 1L
Final working (1 X TBST) buffer concentration: 50 mM Tris-HCl, 150 mM NaCl, 2.7
mM KCl, 0.05 % Tween 20
Blocking Buffer: 5 % non-fat milk dissolved in 1 X TBST buffer

Coomassie Blue Staining
Rinsed the SDS-polyacrylamide gel in ddH2O briefly after protein blotting.
Sufficient volume of different buffers mentioned in Table 12 were used to keep the gel
fully covered. Fixed the gel in fixing solution for 1 hour at room temperature shaking
gently on a shaker. Stained the gel in staining solution for 20 minutes at room
temperature with gentle agitation. Destained the gel in destaining solution, changed the
solution several times, till the background of the gel is fully destained. Stored the
destained gel in storage solution in 4°C in super clean container. The recipe of solutions
used in coomassie blue staining is shown in table 12.
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Table 12. Recipe of solutions used in coomassie blue staining
Coomassie Brilliant Methanol
Blue 250

Glacial Acetic Acid

Percentage of component in different solution (%)
Fixing solution

0

50

10

Staining solution

0.1

50

10

Destaining solution

0

40

10

Storage solution

0

0

5

Immuno-Fluorescence (IF) of Nuclear Proteins
Placed one autoclaved cover slip (20 mm diameter) into a 35 mm X 10 mm cell
culture dish and seeded cells into the dish. Incubated the cells overnight in the cell culture
incubator. Treated cells next day according to the experimental plan (i.e. ionomycin
treatment, drug treatment, UV treatment, etc.). Following the treatment and appropriate
incubation time, placed the cell culture dish on ice. Filled one well of a 6-well plate with
ice-cold 1 X PBS. Moved the cover slip on which cells were seeded to the well. Rinsed
the cells with ice-cold 1 X PBS briefly twice and discarded the PBS. Incubated the cover
slips in the culture dish in 100 % methanol (-20°C) for 10 minutes at -20°C to fix cells
seeded onto the cover slip. Removed the methanol and rinsed the cells with ice-cold 1 X
PBS briefly thrice and discarded the PBS. Blocked the cells with 1 X TBST containing
15 % FBS for 30-60 minute at room temperature on a shaker gently shaking. Discarded
the blocking buffer and rinsed the cells briefly in 1 X TBST. Diluted the primary
antibody in sufficient 1 X TBST containing 15 % FBS as there would be 20 μL of diluted
primary antibody solution for each cover slip. The dilution factors should be determined
for each antibody used since it varied among different antibodies. Pipetted 20 μL of the
55

diluted primary antibody solution onto a section of parafilm. Removed the cover slip
from 1 X TBST and removed the excess buffer from the cover slip by touching one edge
of the clover slip to a Kim-wipe. Carefully and gently placed the cover slip cell-side
down onto the drop of the diluted primary antibody solution avoiding air buffer between
the cover slip and the antibody solution. Repeated for each cover slip. Placed the parafilm
with cover slips on it in a humidifying chamber and incubated for 1 hour at room
temperature. Removed the cover slips from the parafilm gently with forceps and placed
them in the cover slip rack. Rinsed the cover slips in 1 X TBST (3 X 10 minutes). For
fluorescent-conjugated secondary antibody incubation, repeated the processes of primary
antibody incubation and the following cover slips rinsing. Light needed to be avoided for
the whole processes of secondary antibody incubation and following processes. Dropped
one drop (~ 15 μL) of DAPI staining solution on a cover slide. Rinsed the cover slip with
ddH2O once and removed the excess ddH2O from the cover slip by touching one edge of
the cover slip to a Kim-wipe. Carefully and gently placed the cover slip cell-side down on
to the drop of DAPI staining solution avoiding air buffer between the cover slip and the
DAPI staining solution. Repeated for each slip. Waiting for 10 minutes at room
temperature. The cells were ready for taking the immunofluorescent pictures via EVOS
immunofluorescent microscope.

Immunoprecipitation (IP) of Nuclear Extract for Mass Spectrometry or Co-IP of Nuclear
Extract for Protein Interaction Analysis
PierceTM Protein G agarose beads were used for IP. Briefly, cytoplasmic extract
was performed followed the subcellular fraction preparation protocol as mentioned above.
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The washed nuclei of the cells were lysed in ice-cold buffer AB in a 1.5 mL microcentrifuge tube for 15 minutes on ice or on a rotator at 4°C. Nuclear lysate was cleared by
centrifugation at 13,000 rpm for 10 min at 4°C. Gently took the tube out from the
centrifuge and placed on ice. Transferred the supernatant into another pre-ice-cold 1.5
mL micro-centrifuge tube. Added appropriate volume of ice-cold buffer AB to the 1.5
mL micro-centrifuge tube to ensure the total nuclei lysate for each tube is 500 μL. Added
1 μL of anti-PARP1 antibody to each tube. Incubated the mix overnight at 4°C on a
rotator. Added 50 μL of Protein G agarose slurry to the antigen-antibody complex next
day. Incubated the reaction for 2 hours at room temperature on a rotator. Centrifuge the
mix for 20 seconds at 2,500 rcf at room temperature. Transferred the supernatant to
another 1.5 mL micro-centrifuge tube and stored it at 4°C. Added 500 μL ice-cold Co-IP
washing buffer into the tube with the Protein G agarose beads and gently mixed it well
with the beads. Centrifuged tube for 20 seconds at 2,500 rcf and discarded the
supernatant. Repeated this step two more times. Added 60 μL of 2 X SDS loading buffer
to each 1.5 mL micro-centrifuge tube containing Protein G agarose beads. Mixed the
buffer with beads well. Put the tubes in the wells of a dry block to heat the SDS loading
buffer/protein samples mix for 3-5 minutes at 100°C to denature the proteins. The
samples were loaded on 3-8 % gradient gel followed by gel electrophoresis. After the
coomassie blue staining, the destained gel was put in a super-clean plasmid bag with a
little bit ddH2O in it to keep the gel wet. The gel pack was sent out for mass spectrometry.
Buffer AB:
140 mM NaCl
50 mM Tris-HCl pH 7.8
10 % Glycerol
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1 % NP-40
1 mM EDTA
Protease and Phosphatase Inhibitors added fresh before use
Co-IP (Co-immunoprecipitation) Wash Buffer:
140 mM NaCl
50 mM Tris-HCl pH 7.6
10 % Glycerol
0.2 % Tween 20
1 mM EDTA

Recombinant FLAG-ATR Protein Purification
Human kidney HEK293T cells, mammalian expression plasmid pcDNA3.1FLAG-ATR, PierceTM Protein G Agarose beads and anti-FLAG M2 mouse antibody were
used for recombinant FLAG-ATR protein purification. Briefly, HEK293T cells were
seeded overnight ahead of pcDNA3.1-FLAG-ATR plasmid transfection. 4 X 106 cells
were seeded in each 150-mm dish of 8 dishes. Next day, removed the old media and
added 15 mL 37°C-warmed fresh cell culture media to each dish before plasmid
transfection. 20 μg of pcDNA3.1-FLAG-ATR plasmids were used for transfection of one
dish of HEK293T cells. After 48 hours transfection, 8 dishes were put on ice. Discarded
the media and washed the cells with ice-cold 1 X PBS twice gently. Scrapped the cells in
1 X PBS on ice and collected cells by centrifugation for 5 minutes at 5,000 rcf at 4°C.
Lysed the cell pellets in 15 mL ice-cold cellular lysis buffer for 20 minutes at 4°C on a
rotator. Completed the following steps in 4°C cold room. Clarified the cell lysate by
centrifugation at 10,000 rcf for 10 minutes at 4°C. Transferred the clarified lysate
(supernatant) into two Falcon 15 mL conical centrifuge tubes, 7.5 mL per tube. Added 15
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μL of anti-FLAG M2 antibody to each tube of cell lysate. The antibody dilution factor
was 1:500. Rotated the lysate/antibody mix for 2-4 hours. Added 150 μL of Protein G
agarose slurry to each tube of lysate/antibody mix and rotated overnight. The FLAGATR-bound beads were washed gently by wash buffer A briefly twice, high salt wash
buffer A for 3 minutes on a rotator and wash buffer A briefly thrice. Transferred the
FLAG-ATR-bound beads to a pre-ice-cold 1.5 mL micro-centrifuge tube. Recombinant
FLAG-ATR protein was eluted from beads with 0.5 mL elution buffer overnight on a
rotator. Next day, measured the concentration of eluted recombinant FLAG-ATR protein
by following the microplate procedure protocol of Pierce 660 nm Protein Assay Reagent.
If the protein concentration above 100 ng/μL, aliquoted the recombinant FLAG-ATR in
pre-ice-cold 1.5 mL micro-centrifuge tubes, 10 μL/tube. If the protein concentration is
below 100 ng/μL, concentrated the protein by dialysis in elution buffer containing 50 %
glycerol lacking FLAG peptide overnight. Then measured the concentration of FLAGATR and aliquoted them with 5-10 μL/tube. Stored the recombinant FLAG-ATR protein
aliquots in -80°C. Coomassie blue staining and western blot was applied to confirm the
purification of the recombinant FLAG-ATR protein and the purified FLAG-ATR protein
respectively.
Cellular Lysis Buffer:
50 mM HEPES-KOH, pH 7.4
150 mM NaCl
1 mM EDTA
1 % Triton X-100
1 X Protease & Phosphatase inhibitor was added fresh before use
Wash Buffer A:
50 mM HEPES-KOH, pH 7.4
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150 mM NaCl
1 mM EDTA
0.05 % NP-40
High Salt Buffer A:
50 mM HEPES-KOH, pH 7.4
1 M NaCl
1 mM EDTA
0.05 % NP-40
Elution Buffer:
50 mM Tris-HCl, pH 7.5,
150 mM NaCl,
10 % Glycerol,
200 μg/mL FLAG peptide was added fresh before use
1 mM DTT was added fresh before use
1 X Protease & Phosphatase inhibitor was added fresh before use
Dialysis Buffer:
50 mM Tris-HCl, pH 7.5,
150 mM NaCl,
50 % Glycerol,
1 mM DTT was added fresh before use

Recombinant Glutathione S-Transferase (GST)-Pin1 Protein Purification
GST-Pin1 plasmid is a bacterial expression plasmid and was transformed into
BL21 (DE3) E.coli cells for protein expression and purification. Briefly, a sterile
cryogenic storage vial containing the glycerol bacterial stock of GST-Pin1 transformed
BL21 (DE3) E.coli cells stored in -80ºC ultralow temperature freezer was taken out and
put on ice. Using a 10 μL micropipette tip to scrape a small piece of frozen glycerol
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bacterial stock. Dropped the tip into 50 mL LB broth with 100 μg/mL ampicillin.
Incubated overnight at 37°C with 220 rpm. Next day, transferred 40 mL of the overnight
bacteria cell culture into 2 L LB broth with 100 μg/mL ampicillin. Incubated at 37°C
incubator with shaking at 220 rpm. Checked the OD600 of the cell culture media (LB
broth) and only LB buffer every one or two hours. Reduced the incubation temperature to
30°C when the OD600 of the cell culture media reached ~0.5. Adding IPTG into LB broth
when the OD600 of LB broth reached 0.6. The final concentration of IPTG is 1 mM.
Incubated the cell culture at 30°C incubator with shaking at 220 rpm for 5 hours. Harvest
cells by centrifugation for 10 minutes at 6,000 rpm at 4°C. Discarded the cell culture
media, and the cell pellet could be frozen at -80°C ultralow temperature freezer for
completing next steps next day. Re-suspend the cell pellet in 20 mL ice-cold LKB buffer
on ice in one Falcon 50 conical centrifuge tube. Lysed the bacterial cells with sonication
by using the micro-tip horn on ice. One cycle of sonication was sonicating for 10 second
at 25 % intensity, followed by 20 seconds of rest. Repeated 8 cycles of sonication.
Clarified extracts by centrifugation for 10 minutes at 12,000 rpm at 4°C. Transferred the
clarified supernatant evenly into two Falcon 15 mL centrifuge tubes. Completed the
following steps in 4°C cold room. Total 200 μL glutathione agarose beads were used to
rotate with the bacterial cell extracts in 20 mL LKB buffer overnight. The GST-Pin1bound beads were washed with LKB buffer twice gently followed by centrifugation for
20 seconds at 2,500 rpm and discarded the supernatant. The GST-Pin1-bound beads were
eluted with elution buffer for overnight. The eluted fraction was dialyzed with elution
buffer contain 50 % glycerol overnight. The dialyzed GST-Pin1 protein was aliquoted
into 1.5 mL micro-centrifuge tubes with 20 μL per tube. Stored the aliquots at -80ºC
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ultralow temperature freezer. Measured the concentration of dialyze GST-Pin1 protein by
following the microplate procedure protocol of Pierce 660 nm Protein Assay Reagent.
Coomassie blue staining and western blot was applied to checked the purification of the
recombinant GST-Pin1 protein and confirm the purified GST-Pin1 protein respectively.
LKB buffer:
25 mM Tris-HCl, pH 7.5
100 mM NaCl
1 mM EDTA
1 mM EGTA
0.5 % NP-40
25 mM β-glycerophosphate
50 μg/ml phenylmethylsulfony fluoride
10 μg/ml leupeptin, 10 μg/ml aprotinin
1 mM DTT was added fresh before use
Protease and phosphatase inhibitors were added fresh before use
Elute Buffer 1:
25 mM Tris-HCl, pH 7.5,
1 mM EDTA
1 mM DTT was added fresh before use
Elute Buffer 2:
25 mM Tris-HCl, pH 7.5,
1 mM EDTA
1 mM DTT was added fresh before use
10 mM reduced glutathione
Dialysis Buffer:
25 mM Tris-HCl, pH 7.5,
1 mM EDTA
50 % Glycerol
1 mM DTT was added fresh before use
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In-vitro PARylation Assay Using ATR, PARP1, Ca2+ and NAD+, [32P]
The PARylation reaction was performed as described in papers published in 2008
and 2014 (Kedar et al. 2008; Fischer et al. 2014). Briefly, purified PARP1 (20 nM)
purchased from ThermoFisher Scientific, purified ATR (40 nM) from out lab alone, or a
mixture of proteins containing PARP1 (20 nM) or Histone H1 (30 nM) (which are
mentioned in Figure 13A), were incubated in a PARylation reaction buffer (PRB) in 1.5
mL micro-centrifuge tubes. The final volume of the reaction mixture was 40 μL. The
reaction was started by adding 200 μM NAD+,[32P]. Incubated the reaction mix for 30
minutes in the water bath of 30°C. Mixed the reaction mixture several times by gently
tapping the bottom of the 1.5 micro-centrifuge tubes during incubation time period.
PRB buffer:
100 mM Tris-HCl pH 7.8
10 mM MgCl2
1 mM DTT
25 μg/mL activated DNA oligo
200 μM NAD+
40 μL reaction mix
40 nM ATR (0.6 μg)
20 nM PARP1 (0.1 μg)
30 nM Histone H1 (0.05 μg)

Trypan Blue Exclusion Assay
Trypan blue exclusion assay was used to determine cell viability. Dead cells with
broken cell membrane took up trypan blue dye. % viable cells = [1.0 – (number of blue
cells ÷ number of total cells)] X 100. Added 0.1 mL of 0.4 % trypan blue stock solution
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to 1 mL of cell suspension. Counted the number of blue cells and the total number of
cells, within the grids of the hemocytometer, under a light microscope.

CellTiter Blue Cell Viability Assay
CellTiter Blue Cell Viability Assay is based on the ability of living cells to
convert a redox dye (resazurin) into a fluorescent end product (resorufin). The procedure
was following the protocol of the CellTiter-Blue Reagent from Promega. Briefly, cells
were seeded in wells of 96-well microplate one day ahead of the assay. Next day, added
reagent directly to cells in culture, 5 μL per each well. Put the plate back into 37°C cell
culture incubator and incubated for 2 hours. The fluorescence [560Ex/590Em] was
recorded by using a fluorescent microplate reader.

LDH Release Assay
The assay measures the lactate dehydrogenase (LDH) released into culture
supernatants. The released LDH converts a tetrazolium salt (INT) into a red formazan
product. The amount of color formed is proportional to the number of lysed/dead cells.
Briefly, cells were seeded in wells of 96-well microplate one day ahead of the assay.
Next day, following experimental treatment, supernatant samples were transferred to
another 96-well plate and an equal volume (50 μL) of CytoTox 96 Reagent is added to
each well. Lysis Solution was added as 1:10 dilution to some wells for 45 minutes to lyse
all cells as positive control. Incubated the mix for 30 minutes at room temperature
followed by adding 50 μL of Stop Solution in each well. Incubated the mix for 15
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minutes at room temperature. The absorbance signal was measured at 490 nM in a
microplate reader.

Propidium Iodide (PI) Staining
PI is a fluorescent membrane-impermeable dye that stains nuclei by intercalating
between the stacked bases of nuclei acids. It was used to determine the loss of cell
membrane integrity, as it enters cells if the plasma membrane becomes permeable. While
Hoechst 33343 is a cell membrane permeable nuclear counterstain that emits blue
fluorescence when bound to dsDNA. Both dyes were used at the same time in the
experiment to determine the ionomycin-induced percentage of necrotic cell death. Briefly,
after ionomycin treatment, discarded the treated media and washed the cells with 37°Cwarmed 1 X PBS twice gently. Dilute both PI and Hoechst 33342 into 37°C-warmed 1 X
PBS with dilution factor as 1:200. Added PBS containing both dyes to each well to cover
the cells and incubated for 10 minute at 37°C cell culture incubator. Discarded the
staining mix and washed the cells with 37°C pre-warmed 1 X PBS twice gently. Added
pre-warmed PBS into each well to cover the cells fully. Images were taken with EVOS
fluorescent microscope.

Intracellular Calcium Concentration Measurement
HCT116 ATR+/+ and ATRflox/- (ATR-proficient and -deficient) cells were grown
on glass coverslips and then loaded with Fura2 for 30 min at room temperature. Cells
were washed with PBS to remove excess Fura2 and then transferred to an acrylic
chamber on the microscope stage. Fluorescence measurements were recorded as soon as
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cells were placed on the stage (0 min). After 10 min. the normal media was removed and
replaced with media containing calcium (10 mM) and ionomycin (10 μM). Following 10
min incubation, the media was removed and replaced with media lacking calcium.
Recording proceeded for another 10 min after which recording was terminated.
Fluorescence was measured with an imaging system composed of a filter wheel and a
Basler A311F VGA camera connected to an Olympus IX71 inverted microscope.
Automated In Cyte2 software controlled data collection and the filter wheel. Calcium
concentration was measured by interpolation from a standard curve generated by
calibration buffer kit #2 (Molecular Probes) and Fura2/K5-salt. Background fluorescence
was corrected for, and the ratio of the fluorescence at excitation wavelengths (F340/F380)
was monitored in 30-40 cells.
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CHAPTER 3
RESULTS

ATR Plays a Role in Suppressing the Ionomycin-Induced Cell Death
Ionomycin, a Ca2+ ionophore, was used to induce necrosis by increasing
intracellular Ca2+ concentration (Hermann 1978; Vaseva et al. 2012). Data of Figure 26
shows that ionomycin treatment did induce intracellular Ca2+ concentration overload. The
effect of ATR on ionomycin-induced cell death was assessed in different human
fibroblasts and cancer cell lines. Human HCT 116 ATR-proficient and -deficient cells
(ATR+/+ and ATRflox/- cells, respectively) were treated with Ca2+ ionophore ionomycin,
followed by trypan blue exclusion assay to measure the percentage of cell death. As
shown in Figure 10A, a significantly higher cell death was observed in the absence of
ATR than in the presence of ATR. CellTiter-blue cell viability assay (Figure 10B) also
showed that cells had significantly lower viability, after ionomycin treatment, in the
absence of ATR than in the presence of ATR. The results suggest that ATR enables cells
to resist the ionomycin-induced cell death. In addition, ATR was knocked down in
different human cancer cells (A549 and U2OS) and fibroblast cells (A1, passage 18)
using small interfering RNA (siRNA) specific to ATR (Figure 10C, 10D and 10E).
Trypan blue exclusion assay showed that ionomycin treatment induced significantly more
cell death in ATR-siRNA knockdown (siATR) cells than in siRNA control cells
(siCTRL). High mobility group box 1 (HMGB1) is a nuclear protein bound to the
chromatin under normal condition. HMGB1 is released into cell culture media when
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necrosis happens (Harris and Andersson 2004; Zong and Thompson 2006; Han et al.
2008; Cho et al. 2010). The cell-to-media release of HMGB1 is a marker of necrotic cell
death. Western blot (WB) analysis of TCA-precipitated media protein using HMGB1
antibody showed that significantly more HMGB1 was released into media from cells in
the absence of ATR than from cells in the presence of ATR (Figure 10F). This result
indicates that ATR may play a role in suppressing the ionomycin-induced necrotic cell
death. Since ATR is well known for its regulatory role in DDR, it is of interest to
determine whether the role that ATR plays in suppressing ionomycin-induced cell death
is DNA damage dependent. As shown in Figure 10G, WB analysis showed that although
the DNA strand-break marker (γH2AX) and DDR markers (p-p53 (S15) and p-Chk1
(S345)) were detected in UV-treated cells, none of them were detected in ionomycintreated cells. Taken together, all above results indicate that ATR may play an antinecrotic role in suppressing the ionomycin-induced cell death. This anti-necrotic activity
of ATR is likely part of cell non-DNA damage stress response (NDDR).
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Figure 10. ATR plays a role in NDDR by suppressing the ionomycin-induced cell death.
(A) Human ATR+/+ and ATRflox/- cells were treated with ionomycin (10 μM) for the
indicated periods before cell death rate in percentage was measured using the trypan blue
exclusion assay. Western blot (WB) analysis of ATR expression in ATR+/+ and ATRflox/cells. (B) ATR+/+ and ATRflox/- cells were treated with ionomycin as indicated followed
by the measurement of the loss of cell viability in percentage using the CellTiter-blue cell
viability assay. (C, D & E) Human A549 cells, U2OS cells, or A1 fibroblast cells
(passage 18) were transfected with siRNA specific for ATR followed by ionomycin
treatment as indicated, then the percentage of cell death was measured by empolying
trypan blue exclusion assay. WB analysis of ATR knockdown in cells. (F) ATR+/+ and
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ATRflox/- cells were treated with ionomycin for 4 hours. Media proteins were precipitated
by TCA precipitation assay. WB analysis of HMGB1 released into media as GAPDH in
whole cell extract (WCE) as loading control. (G) A549 cells were treated either with UVC 40 J/m2 followed by recovery for 2 hours or with ionomcyin (10 μM) for 4 hours. WB
analysis of WCE for the DDR marker: γH2AX (p-H2AX(S139)), p-p53(S15) and pChk1(S345).

Necrosis is the Exclusive Form of Cell Death Induced by Ionomycin
Cell morphology-based assay was employed to analyze the cell death induced by
ionomycin and apoptosis-inducer camptothecin (CPT). As shown in Figure 11A,
ionomycin-induced Ca2+ overload resulted exclusively in necrotic cell death characterized
by cellular swelling, while CPT treatment efficiently induced apoptosis as characterized
by cellular shrinkage and the formation of apoptosis bodies (Proskuryakov et al. 2003;
Festjens et al. 2006; Krysko et al. 2008). The quantification of data from Figure 11A
(Figure 11B) showed that significantly more necrosis was induced by ionomycin in ATRdeficient cells than in ATR-proficient cells. WB analysis showed that CPT treatment, not
the ionomycin treatment, induced cleavage of caspase-3, caspase-7 and PARP1 in both
ATR+/+ and ATRflox/- cells (Figure 11C and 11D). Since the cleavage of caspase-3,
caspase-7 and PARP1 are the apoptotic molecular events (Kaufmann et al. 1993;
Lazebnik et al. 1994; Boulares et al. 1999; Ha and Snyder 1999; Kitanaka and Kuchino
1999; D’Amours et al. 2001; Bröker et al. 2005), the results further confirm that
ionomycin-induced Ca2+ overload induces necrosis exclusively. Furthermore, ATR+/+ and
ATRflox/- cells were pre-incubated with mock or Z-VAD-FMK (10 μM, 1 hr), a broad
spectrum caspase inhibitor (Slee et al. 1996), followed by mock or ionomycin treatment.
The percentage of cell death was measured using trypan blue exclusion assay. As shown
in Figure 11E, apoptosis inhibitor Z-VAD-FMK pre-incubation did not significantly
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affect ionomycin-induced cell death rate, in percentage, in ATR-proficient and -deficient
cells, and there was significantly higher ionomycin-induced necrosis in the absence than
in the presence of ATR. The results from Figure 11A-11E suggest that necrosis is the
unique form of cell death induced by ionomycin-induced Ca2+ overload and ATR plays a
role in suppressing the ionomycin-induced necrosis.

Figure 11. Necrosis is the exclusive form of cell death induced by ionomycin. (A) ATR+/+
and ATRflox/- cells were treated with either ionomycin (10 μM, 4 hrs) or apoptosis inducer
camptothecin (CPT) (10 μM, 24 hrs) followed by phase-contrast imaging (20 X).
Necrosis characterized by cellular swelling and nuclear shrinkage was exclusively
induced by ionomycin treatment. (B) Quantification of morphologic analysis in B. (C &
D) WB analysis of the cleavage of caspase-3, caspase-7 and PARP1 in ATR+/+ and
ATRflox/- cells treated with either ionomycin or CPT as in B. (E) ATR+/+ and ATRflox/71

cells were pre-incubated with apoptosis inhibitor A-VAD-FMK (10 μM, 1 hr) or mock
treatment followed by mock or ionomycin treatment (10 μM, 4 hrs) before the percentage
of necrotic cell death was measured using trypan blue exclusion assay.

Ionomycin Treatment Hyper-Activates the Poly(ADP-ribosyl)ation (PARylation)
Activity of PARP1
Necrosis is characterized by bio-energetic catastrophe due to the ATP pool
depletion induced by hyper-activation of PARP1. PARP1can hydrolyze NAD+ into NAM
and ADPr and covalently connect the ADPr units to its protein targets or itself to form
poly(ADP-ribose) (PAR) polymers. Hyper-activation of PARP1 leads to excessive
consumption of NAD+ pool, which causes the ATP depletion in cells, and then induces
necrosis. We proposed that ionomycin induces necrosis via hyper-activation of PARP1.
A549 cells were treated with ionomycin for indicated periods (Figure 12A), followed by
WB analysis of formation of PAR polymers using anti-PAR antibody. As shown in
Figure 12A, ionomycin-induced formation of PAR polymers was time-dependent. Next,
A549 cells were treated with ionomycin in the presence of PARP inhibitors, 3-ABA or
AG-14361, followed by WB analysis of PAR polymers formation. Figure 12B and 12C
show that inhibition of PARP suppressed the ionomycin-induced formation of PAR
polymers. It was reported that PARP1 is responsible for about 90% of cellular PAR
polymers formation under DNA damage (D’Amours et al. 1999; Bürkle 2005; Yelamos
et al. 2011). It is of interest to determine whether PARP1 is responsible for the
ionomycin-induced formation of PAR polymers or not. As shown in Figure 12D,
compared with ionomycin-induced formation of PAR polymers in control cells, cells with
PARP1 knockdown failed to form PAR polymers. The result indicates that PARP1 is
responsible for the ionomycin-induced formation of PAR polymers. We further used
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human A549 shPARP1 and shCTRL cells, a gift from Dr. Csaba Szabo and Dr. Laszlo
Virag. These cells are A549 cells transfected with short hairpin RNA (shRNA) specific
to PARP1 or control shRNA (Erdélyi et al. 2009). WB analysis of PARP1 expression in
shCTRL and shPARP1 cells is shown in Figure 12G. Immunofluorescence (IF) assay
(Figure 12E) shows that ionomycin treatment induced formation of PAR polymers only
in shCTRL cells, but not in shPARP1 cells. Data in Figure 12D and 12E confirm that
PARP1 is responsible for the ionomycin-induced formation of PAR polymers.
Furthermore, propidium iodide (PI) as a cellular membrane impermeable fluorescent dye
was used to measure the percentage of necrotic cell death after ionomycin treatment. As
shown in Figure 12F and 12G, there was significantly more necrosis in shPARP1 cells
than in shCTRL cells. Figure 12H shows that PARP1 overexpression in shPARP1 cells
sensitized cells to ionomycin-induced necrosis. The results suggest that necrosis is caused
by ionomycin-induced hyper-activation of PARP1. In support, supplementation of NAD+
to media can recue A549 cells from ionomycin-induced necrosis as determined by LDH
release assay (Figure 12I). The result supports that NAD+ pool excessive consumption by
hyper-activated PARP1 is the cause of necrosis. Taken together, all these results suggest
that ionomycin-induced hyper-activation of the PARylation activity of PARP1 is the
cause of necrosis.
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Figure 12 (continued to the next page)
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Figure 12. Ionomycin treatment hyper-activates the PARylation activity of PARP1. (A)
A549 cells were treated with ionomycin (10 μM) as indicated time period, followed by
WB analysis of formation of PAR polymers using anti-PAR antibody. (B & C) A549
cells were treated with ionomycin (10 μM, 4 hours) following pre-incubation with potent
PARP1 inhibitor (either 3-ABA or AG14361). Formation of PAR polymers are detected
by WB analysis using anti-PAR antibody. (D) A549 cells were transfected with siRNA
specific for PARP1 or negative control siRNA, followed by ionomycin (10 μM) or mock75

treatment for indicated periods. Cell lysates were analyzed by WB for PARylation using
anti-PAR antibody. (E) Human A549 shPARP1 and shCTRL cells were treated with
ionomycin (10 μM) or mock for 2 hours, followed by immunofluorescence staining using
indicated antibodies. Fluorescence microscopy images were taken with 20 X objective. (F)
shCTRL and shPARP1 cells were treated with ionomycin or ethanol as mock as
mentioned in E, followed by PI staining. (G) Quantification of data from F and WB
analysis of PARP1 expression in shCTRL and shPARP1 cells. (H) PARP1-overexpressed
shPARP1 cells were treated with ionomycin or ethanol for mock, followed by trypan blue
staining. (I) Cell culture media of A549 cells supplemented with or without NAD+ (10
mM) for 1 hour before the ionomycin (10 μM, 2 hours) treatment, followed by
measurement of loss of cell viability via LDH assay.

Ionomycin Treatment Promotes Physical Interaction of ATR and PARP1 for Suppressing
Necrosis
Based on the results of Figures 10-12, we hypothesized that ATR plays a role in
suppressing the ionomycin-induced hyper-activation of PARP1. Figure 13A shows that
cells had much less ionomycin-induced PAR polymers in the presence of ATR than in the
absence of ATR. Also, the ionomycin-induced PAR polymer formation dramatically
increased in A549 cells pre-incubated with VE822 as shown in Figure 13B. VE822 was
reported as an inhibitor of ATR in 2012 (Fokas et al. 2012). Figure 13A and 13B indicate
that ATR plays a role in suppressing the ionomycin-induced PAR polymers. In addition,
A549 cells were treated with ionomycin or ethanol (mock) followed by fractionation to
isolate cytoplasmic fraction (CyF) and nuclear fraction (NuF). ATR immunoprecipitation
(IP) from CyF and NuF to check how much PARP1 interact with ATR. As shown in
Figure 13C, there is hugely increasing of PARP1 co-IPed from ATR in the NuF of
ionomycin-treated cells than PARP1 co-IPed from ATR in the NuF of ethanol-treated
cells. The result indicates that ionomycin treatment induces ATR-PARP1 binding. The
same also was true in HCT116 cells as shown in Figure 13D. Alternatively, proximity
ligation assay (PLA) technology is capable of reporting protein-protein interactions in
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fixed cells (Gustafsdottir et al. 2005; Söderberg et al. 2008). As shown in Figure 13E,
ATR-PARP1 complexes were found in ionomycin-treated cells rather than mock-treated
cells. The quantification of the PLA data shows that ionomycin treatment induced ATRPARP1 interaction. Data from Figure 13C-13E demonstrate that ionomycin treatment
induces ATR physical interaction with PARP1.

Figure 13. Ionomycin treatment induces ATR physical interaction with PARP1 for
suppressing necrosis. (A) WB analysis of PAR polymers in ATR+/+ and ATRflox/- cells
treated with ionomycin (10 μM) as indicated using anti-PAR antibody. (B) WB analysis
of PAR polymers in A549 cells treated with ionomycin (10 μM, 4 hrs) in the presence or
absence of ATR inhibitor VE822 (10 μM, 1hr pre-incubation). (C) A549 cells were
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treated with ionomycin (10 μM) for 4 hours, followed by fractionation. ATR was
immuno-precipitated (IPed) both in cytoplasmic and nuclear fraction (CyF and NuF,
respectively) using anti-ATR antibody. WB was employed for analysis of coimmunoprecipitation (Co-IP) of PARP1 with ATR. ATR was probed in WB using antiATR antibody for loading control. The heavy chain of IgG serves as loading control. (D)
Human HCT116 cells were treated with ionomycin followed by fractionation and ATRIP as mentioned in C. (E) A549 cells were treated with ionomycin (10 μM, 2 hrs)
followed by PLA immunoassay to detect ionomycin-induced ATR-PARP1 binding using
anti-ATR and anti-PARP1 antibodies and PLA technology. Fluorescent red dots indicate
ionomycin-induced ATR-PARP1 complexes (20 X objective). The quantification the
PLA assay is shown on the right side.

The Anti-Necrosis Function of ATR Is ATR Kinase Activity Dependent
Since it was demonstrated that ionomycin treatment induces ATR physical
interaction with PARP1 (Figure 13C-13E) and ATR is well known as a protein kinase, it
is of interest to determine whether ATR phosphorylates PARP1. Thus, A549 cells were
treated with ionomycin (10 μM) (Figure 14A). WB analysis of the cell lysates show that
ionomycin-induced phosphorylation of ATR at threonine 1989 was time-dependent. It
was demonstrated that Thr-1989 phosphorylation is a marker for activation of ATR
kinase (Nam 2011). We hypothesized that the kinase activity of ATR is essential for its
anti-necrosis role. U2OS cells were dominant negative mutant. After 16-24 hours
doxycycline (5 μg/mL) induction, ATR-wild type (WT) protein expressed in U2OS ATRWT cells and ATR-kinase dead (KD) protein expressed in U2OS ATR-KD cells. Figure
14B shows that ionomycin-induced ATR-PARP1 binding occurred in U2OS ATR-WT
cells but not in U2OS ATR-KD cells. As shown in Figure 14C, PI staining assay shows
that U2OS ATR-KD cells had significantly more ionomycin-induced necrosis than U2OS
ATR-WT cells. The quantification of the assay is shown as Figure 14D. The kinase
activity of ATR-WT protein and ATR-KD protein in U2OS cells was confirmed in
Figures 27A and 27B. Mammalian expression ATR-WT and ATR-KD plasmids were
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transiently expressed in ATRflox/- cells separately. Figure 14E shows that cells (ATRflox/cells) transiently expressed ATR-WT protein were much more resistant to ionomycininduced necrosis than cells (ATRflox/- cells) transiently expressed ATR-KD protein. These
results (Figures 14B-14E) indicate that ATR kinase activity is required for ionomycininduced ATR-PARP1 binding and enables cells to be more resistant to ionomycininduced necrosis. In addition, shCTRL and shPARP1 cells were treated with ionomycin
in the presence of VE822. The trypan blue exclusion assay shows that inhibition of ATR
did not affect the percentage of necrosis induced by ionomycin treatment in PARP1
deficient (shPARP1) cells. By contrast, in the presence of PARP1 (shCTRL cells),
inhibition of ATR significantly increased the ionomycin-induced necrosis (Figure 14F).
The result indicates that ATR and PARP1 work in the same ionomycin-induced necrosis
pathway.

Figure 14 (continued to the next page)
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Figure 14. The anti-necrosis function of ATR is ATR kinase activity dependent. (A)
A549 cells were treated with ionomycin (10 μM) as indicated, followed by WB analysis
of the phosphorylation of ATR at threonine 1989 using anti-pATR-T1989 antibody. The
positive control of phosphorylation of ATR at threonine 1989 was from A549 cells
treated with 40 J/m2 UV followed by 2 hours recovery. (B) U2OS ATR-WT and ATRKD cells were treated with doxycycline (5 μg/mL) for 16-24 hours for induction of ATRWT and ATR-KD protein expression, followed by ionomycin or mock treatment for 4
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hours. ATR IPed from whole cell extract (WCE) using anti-ATR antibody, followed by
WB analysis of PARP1 that was co-IPed with ATR using anti-PARP1 antibody. Heavy
chain of IgG was used as a loading control. The experiment was done by Dr. Benjamin A.
Hilton. (C & D) ATR-WT and ATR-KD protein in U2OS ATR-WT and U2OS ATR-KD
cells induced as mentioned in B, followed by ionomycin or mock treatment for 2 hours.
The percentage of necrotic cell death was measured by PI staining assay via fluorescent
microscopy (20 X objective) (C). The quantification of the data from C is shown in D. (E)
ATR-WT and ATR-KD plasmids were transiently transfected into ATRflox/- cells for two
days, followed by ionomycin treatment (10 μM, 4 hours). The percentage of necrotic cell
death was measured using trypan blue exclusion assay. WB analysis of ATR-WT and
ATR-KD protein expression in ATRflox/- cells using anti-ATR antibody. (F) shCTRL and
shPARP1 cells were treated with ionomycin (10 μM, 4hrs) in the presence or absence of
ATR inhibitor VE822 (10 μM, 1hr pre-incubation), followed by trypan blue exclusion
assay to measure the percentage of necrotic cell death.

Ca2+ Hyper-Activates the PARylation Activity of PARP1 and Primes PARP1 for ATR
Binding
Figure 26 and Figure 12 demonstrate that ionomycin treatment-induced
intracellular Ca2+ concentration spike and hyper-activated PARylation activity of PARP1.
A hypothesis was that Ca2+ by itself can hyper-activate PARP1. An in vitro PARylation
assay with isotope NAD+-32P (Fischer et al. 2014) was performed to test the hypothesis.
If adding Ca2+ could hyper-activate PARP1 by forming PAR polymers, it shows that
hyper-activation of PARP1 is Ca2+ dependent. The full-length of PARP1 protein on the
SDS-PAGE gel is around 110 kD, the smeared bands above 110 kD are PAR-modified
PARP1. Figure 15A (lanes 4 and 5), shows that adding activated DNA oligos into
PARylation reaction buffer (PRB) can activate PARylation activity of PARP1 as
expected. There were PAR polymers (lane 5) shown as smear bands compared with little
or no PAR polymers (lane 4). Interestingly, Ca2+ by itself can activate PARP1 to generate
PAR polymers, the smeared bands between 110 kD and 150 kD, on PARP1 without
activated DNA oligos (mimic DNA damage) (lane 3). While those smeared bands were
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around 110 kD when purified ATR was incubated in PARylation reaction buffer with
Ca2+ and PARP1 at the same time (lane 2 & lane 3). The bands around 110 kD represents
that the PAR polymers on PARP1 were much shorter than the PAR polymers on PARP1
represented by bands concentrated around 150 kD. Next experiment, Ca2+ was added to
the whole cell lysate buffer followed by ATR-IP to allow the analysis of the PARP1 coIPed from ATR via WB analysis. As shown in Figure 15B and 15C, adding Ca2+ into the
lysate buffer did induce ATR-PARP1 binding (Figure 15B) and more PARP1 co-IPed
with ATR as higher concentrated Ca2+ added into lysate buffer (Figure 15C). Figure 15A
indicates that Ca2+ hyper-activates PARP1. Figure 15B and 15C suggest that Ca2+
overload may primer PARP1 for ATR binding. All these results lead to the hypothesis
that ATR binding to the PAR-modified PARP1 is the cause of ionomycin-induced ATRPARP1 binding. Poly(ADP-ribose) glycohydrolase (PARG) is an enzyme which is
responsible for PAR hydrolysis to release ADRr from proteins at the PAR modification
sites of protein, leaving MAR-modified proteins (Vyas et al. 2014). It was used in our
experiment to check whether ATR tends to bind PAR-modified PARP1 or not. Purified
PARP1 protein was IPed followed by in vitro PARylation assay. The PAR modified
PARP1 was treated with or without PARG, followed by incubating with purified ATR
protein. As shown in Figure 15D, WB analysis shows that ATR bound to PARP1 only
treated with PARylation assay. Instead, ATR did not bind to PARP1 treated with
PARylation assay firstly then followed by PARG incubation. The result indicates that
ATR tends to bind PAR-modified PARP1 instead of MAR-modified PARP1.
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Figure 15. Ca2+ itself hyper-activates the PARylation activity of PARP1 and may prime
PARP1 for ATR binding. (A) In vitro, the PARylation activity of PARP1, with different
proteins or chemicals, was performed by PARylation assay using NAD+, [32P]. Protein
PARP1 incorporated with NAD+, [32P] was separated on 8% SDS-PAGE gel, followed
by gel transferring to PVDF membrane. The PARylated PARP1 was shown by radio
autography imaging. (B) A549 cells were ionomycin (10 μM, 4 hrs) or mock treated,
followed by lysing in buffer AB with or without 1 μM Ca2+ as indicated. ATR was IPed
from each lysate using anti-ATR antibody, then WB analysis was employed to analysis
PARP1 co-IPed with ATR via PARP1 antibody. Both ATR and heavy chain of IgG
probed as loading controls. (C) A549 cells were ionomycin (10 μM, 4 hrs) treated,
followed by lysing in buffer AB with or without Ca2+ as indicated. ATR IPed from lysate,
and WB analysis was employed to detect PARP1 co-IPed with ATR as mentioned in B.
(D) Purified PARP1 was IPed using anti-PARP1 antibody, followed by in vitro
PARylation assay. PAR-modified PARP1 was treated with or without PARG, followed
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by incubating with purified ATR protein. WB analysis was employed to analysis ATR
that co-IPed with PARP1 via using ATR and PARP1 antibody.

Mass Spectrometric Determination of the Potential ATR Phosphorylation Site on PARP1
and PARP1 Plasmid Mutagenesis
Figures 13 and 14 show that ATR kinase activity is required for ionomycin-induced ATR
physical interaction with PARP1, and ATR kinase activity is needed for suppressing
ionomycin-induced hyper-activation of the PARylation activity of PARP1. The
hypothesis was that ATR may phosphorylate PARP1. Mass spectrometry was used to
detect the candidate ATR phosphorylation site(s) on PARP1. PARP1 was IPed from
ionomycin- or ethanol (mock)-treated A549 cells as mentioned in Figure 16A, followed
by SDS-PAGE gel electrophoresis and coomassie blue staining. Band A and band B were
cut out from SDS-PAGE gel separately for mass spectrometry to detect phosphorylation
site(s) on PARP1. Mass spectrometry analysis (Figure 16B) shows that 66.32% of
threonine (Thr) 368 on PARP1 was phosphorylated in mock-treated cells, while 99.98%
was phosphorylated in ionomycin-treated cells. WB analysis confirms that cells had more
PARP1 phosphorylated at Thr 368 in ionomycin-treated cells than in mock-treated cells
using anti pPARP1-T368 antibody, shown in Figure 16C. It is of interest to examine the
ionomycin-induced necrotic cell death and ATR-PARP1 interaction in cells that have
mutated PARP1 protein at site T368 versus cells that have wild type PARP1. PARP1
plasmid mutagenesis was done to generate the mutated PARP1 protein at site 368 from
Thr to Ala. Figure 16D shows the sequence alignment of the mutated mammalian
expression human PARP1-T368A plasmid with PAPR1-WT plasmid. It confirmed that
cDNA sequence of PARP1 was mutated from ACG (Thr) to GCG (alanine, Ala).
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Figure 16. Mass spectrometry to determine the candidate ATR phosphorylation site on
PARP1. (A) Coomassie blue staining of PARP1 IPed from mock or ionomycin-treated
A549 cells on 8% SDS-PAGE gel. (B) Phosphorylation site on PARP1 detected by mass
spectrometry. (C) WB analysis of phosphor-PARP1 at threonine 368 in A549 cells
treated with ionomycin (10 μM, 4 hrs) or mock. (D) PARP1-T368A plasmid sequence
alignment with PARP1-WT plasmid.

Other Potential ATR Phosphorylation Sites on PARP1

In addition to mass spectrometry, SQ/TQ motifs of PARP1 are considered to be
candidate ATR phosphorylation sites (Traven and Heierhorst 2005; Kim et al. 1999;
O’Neill et al. 2000). There are six sites on PARP1 which are SQ/TQ motifs as shown in
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Table 13. It is of interest to check the ionomycin-induced necrotic cell death and ATRPARP1 interaction in cells expressing mutated PARP1 protein at each of those candidate
ATR phosphorylation sites respectively, compared with cells that have wild type PARP1.
Site-directed mutagenesis of those six sites on PARP1 was done to generate mutated
PARP1 protein with each site mutated to alanine. Figures 17A-17F show the sequence
alignment of PARP1-WT plasmid with each mutated PARP1 plasmid (PARP1-S179A,
PARP1-T325A, PARP1-S721A, PARP1-S727A, PARP1-S874A and PARP1-S911A).
Table 13. SQ/TQ motifs on PARP1
SQ/TQ
Amino acid number

SQ

TQ

179,721,727,874,911

325

Figure 17 (continued to the next page)
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Figure 17. Site-directed mutagenesis of PARP1-WT plasmid. (A) – (F) Sequence
alignment of PARP1-WT with each mutated PARP1 plasmid (PARP1-S179A, PARP1T325A, PARP1-S721A, PARP1-S727A, PARP1-S874A and PARP1-S911A).

Candidate Ca2+ Binding Site (CaBS) on PARP1
Ca2+-binding proteins usually containing EF hand domain. EF hand loop of EF
hand loop is important for Ca2+ binding and it is composed of 12 amino acids (LewitBentley 2000). Based on the consensus of EF hand loop (Figure 18A), the fragment of
PARP1 from aspartic acid (Asp, D) 957 to D968 was shown as a potential Ca2+-binding
site with 92% similarity with consensus of EF hand loop (Figure 18A). The PARP1
fragment (D957-D968) is named here as Ca2+-binding site (CaBS). Since aspartic acids in
the EF hand are important for Ca2+ binding (Bentley 2012), D965 or/and D968 sites were
chosen to be mutated to asparagine (N). As shown in Figure 18B, the sequence alignment
of PARP1-WT plasmid with mutated PARP1-D968N plasmid shows that cDNA
sequence of PARP1 was mutated from GAC (D) to AAC (N). Figure 18C shows the
sequence alignment of PARP1-WT plasmid with mutated PARP1-D965D968N plasmid
in which the cDNA sequence of PARP1 was mutated from GAT (D965) to AAT (N965)
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and from GAC (D968) to AAC (N968). Figure 18D shows the sequence alignment of
PARP1-WT plasmid with PARP1-∆CaBS plasmid where the cDNA fragment of CaBS is
deleted from PARP1-WT plasmid. A549-shPARP1 cells will be used as transiently
expressing PARP-WT and PARP1-∆CaBS plasmids separately. In vitro PARylation
assay will be employed to test whether both PARP1 proteins’ activity hyper-activation is
Ca2+ dependent or not.

Figure 18. Determine the candidate Ca2+ binding site (CaBS) on PARP1. (A) The
fragment of PARP1, D957-D968, was shown as a candidate calcium binding site (CaBS)
based on protein database scanning via PATTINPROT online from “PRABI-GERLAND
PHONE-ALPES BIOINFORMATIC POLE GERLAND SITE”. Consensus pattern for
calcium-binding of EF hand loop is “D-x-[DNS]-{ILVFYW}-[DENSTG]-[DNQGHRK]{GP}-[LIVMC]-[DENQSTAGC]-x(2)-[DE]” (modified from website
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“http://www.uniprot.org/help/ca_bind”). The interpretation of standard International
Union of Pure and Applied Chemistry (IUPAC) one-letter codes, ‘x’ any amino acid is
accepted at the position, ‘[]’ residues indicated in square parentheses are those allowed at
the position, ‘{}’ residues indicated in curly brackets are those forbidden at the position.
‘-’ separates each pattern element. (B) PARP1-WT was mutated to PARP1-D968N. (C)
PARP1-WT mutated to PARP1-D965ND968N. (D) PARP1-WT was mutated to PARP1∆CaBS with CaBS deletion.

PARP1-WT Plasmid Site-Directed Mutagenesis at Glutamic Acid (Glu, E) 988
Glutamic acid (E) 988 on C-terminal catalytic domain of PARP1 was previously
shown to be essential for the synthesis (especial the elongation) of enzyme-linked PAR
polymers (Rolli et al. 1997). Mutation of E988 on PARP1 to lysine (Lys, K) or glutamine
(Gln, Q) was reported to lead to the MAR modification only (Chapman et al. 2013).
Figure 19A shows the sequence alignment of PARP1-WT plasmid with mutated PARP1E988K plasmid as the cDNA sequence of PARP1 mutated from GAG (E) to AAG (K).
Figure 19B shows the sequence alignment of PARP1-WT plasmid with mutated PARP1E988Q plasmid as the cDNA sequence of PARP1 mutated from GAG (E) to CAG (Q).
A549-shPARP1 cells will be used as transiently expressing PARP-WT, PARP1-E988K
and PARP1-E988Q plasmids separately. After ionomycin treatment, PARP1 will be coIPed together with ATR. WB will be employed to analyze whether ATR tends to bind
either PAR-modified or MAR-modified PARP1.
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Figure 19. PARP1-WT plasmid site-directed mutagenesis at glutamic acid (Glu, E) 988
residue. (A) Plasmid PARP1-WT was mutated to PARP-E988K. (B) Plasmid PARP-WT
was mutated to PARP1-E988Q.
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CHAPTER 4
DISCUSSION

ATR Plays an Anti-necrosis Role in Response to Ionomycin-Induced NDDR
ATR is well known for its regulatory role in DDR as a checkpoint kinase. For
example, in response to UV irradiation-induced DNA damage, ATR plays a role in
suppressing apoptosis through the ATR-Chk1 pathway (Heffernan et al. 2009) or directly
at mitochondria via interacting with tBid (Hilton et al. 2015). In addition, ATR promotes
nucleotide excision repair (NER) via physical interaction with xeroderma pigmentosum
group A (XPA) (Wu et al. 2007; Shell et al. 2009). Our work indicates that ATR plays a
role in response to NDDR for the first time. As shown in Figure 10G, DNA damage and
DDR markers, γH2AX, pp53-S15, pChk1-S345 (Liu et al. 2000; Meek 2009; Mah et al.
2010), were not detected in the ionomycin-treated cells using WB analysis, while all of
them were detected in UV-irradiated cells.
Trypan blue exclusion assay (Figures 10A, 10C, 10D and 10E) and CellTiter blue
cell viability assay (Figure 10B) were performed to measure ionomycin-induced the rate
of cell death in percentage in ATR-deficient, ATR-proficient and ATR-knockdown cells
respectively. All results suggest that ATR may play a role in suppressing the ionomycininduced cell death. Cell morphology-based assay (Figure 11A and 11B) and HMGB1
release assay (Figure 10F) also support the anti-necrosis function of ATR. Furthermore,
WB analysis of the cleavage of caspase-3, caspase-7 and PARP1 (Figure 11D and 11D)
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and trypan blue exclusion assay using apoptosis inhibitor Z-VAD-FMK (Figure 11E)
demonstrate that ATR possesses an anti-necrosis function in cells.
The concept of ATR plays an anti-necrotic role in respond to NDDR in cells is
pretty novel and has not been proposed or studied previously. Necrosis was believed a
disorderly and unregulated process and ATR is well known for its regulatory role in DDR
as a checkpoint kinase. Our data show that ATR possesses an anti-necrosis function in
cells and figuring out the mechanism behind it turns out to be very interesting.

Ionomycin-Induced Hyper-Activation of PARylation Activity of PARP1 Is Ca2+
Dependent
Ionomycin is well known as a Ca2+ ionophore to raise intracellular level of Ca2+.
It induces intracellular Ca2+ concentration and induces necrosis (Hermann 1978; Vaseva
et al. 2012). The intracellular Ca2+ concentration during ionomycin treatment was
measured using Fura-2. In our experiment, ionomycin treatment raises the intracellular
Ca2+ concentration. As shown in Figure 26, the intracellular Ca2+ concentration increased
immediately once cells were treated with ionomycin, and the concentration reached ~700
nM in ATR-proficient cells and ~1 µM in ATR-deficient cells 10 minutes after
ionomycin incubation. Under physiological conditions, cells maintain a cytosolic freeCa2+ concentration of roughly 100 nM. A spike of cytosolic Ca2+ to 200-400 nM due to
release from the endoplasmic reticulum (ER) can induce apoptosis. In contrast, a
cytosolic overload of Ca2+ resulting from influx across the plasma membrane triggers
necrosis (McConkey and Orrenius 1996; Zong and Thompson 2006). The result from
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Figure 26 indicates that ionomycin incubation (10 μM, 4 hrs) may initiate necrosis by
inducing the intracellular Ca2+ concentration overload.
Active PARP1 hydrolyzes NAD+ into NAM and ADPr and covalently transfers
ADPr to its substrates or itself to form 90% of PAR polymers within cells (D’Amours et
al. 1999; Amé et al. 2004; Bürkle 2005; Yelamos et al. 2011; Vyas et al. 2014).
Excessive consumption of NAD+ is the cause of necrosis due to the cellular metabolism
collapse. Lactate dehydrogenase (LDH) release assay (Figure 12I) showed that supplying
media with NAD+ can rescue cells from ionomycin-induced necrosis. Why? One
explanation may the NAD+ pool depletion is caused by ionomycin-induced hyperactivation of PARP1. As shown in Figure 12B, 12C and 12D, cells either treated with
potent PARP1 inhibitors or transfected with siPARP1 are devoid of ability of to form
PAR polymers after ionomycin treatment. Figures 12E, 12F and 12G further confirm
that PARP1 is required for ionomycin-induced formation of PAR polymers and necrosis.
The next question is how ionomycin treatment induces hyper-activation of
PARP1? Several papers reported that Ca2+ as a mediator of necrotic cell death is
responsible for the hyper-activation of PARP1-induced necrosis due to NAD+/ATP
depletion in cells (Bentle et al. 2006; Yang et al. 2007; Francis et al. 2013; Douglas and
Baines 2014; Zhang et al. 2014). But no mechanism study was mentioned. The present in
vitro work (Figure 15A) showed that Ca2+ can hyper-activate PARP1. As the positive
control, adding activated oligo DNA in the PARylation reaction buffer (PRB) can hyperactivate PARP1, which is shown as the formation of PAR polymers (Figure 15A, lane 4
and lane 5). Interestingly, PAR polymers were formed in PRB with Ca2+ instead of
activated oligo DNA (Figure 15, lane 3). Ca2+ itself can hyper-activate PARP1. Maybe
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there is CaBS on PARP1 as we have identified a potential CaBS on PARP1 which has a
consensus sequence pattern with EF hand loop (Figure 18A). PARP1 plasmids with sitedirected mutation at CaBS were produced for future determination of the mechanism of
Ca2+-dependent hyper-activation of PARP1. The future study of Ca2+-dependent hyperactivation of PARP1 via CaBS may help us to define how Ca2+ hyper-activates PARP1.

Ionomycin Treatment Induces ATR-PARP1 Binding and ATR Modifies the Full-Length
PAR Polymer Formation
Our work demonstrates that ionomycin treatment induces ATR-PARP1 binding in
cells (Figure 13C-E), and the binding appears to suppress necrosis via inhibiting
formation of full-length PAR polymers formed by PARP1 (Figure 13A and 13B, Figure
15A). ATR’s kinase activity is involved in suppressing ionomycin-induced necrosis
(Figure 14B-E), but what it is mentioned here focus on ATR-PARP1 binding through
PAR modification. Ionomycin-induced formation of PAR polymers largely increased in
cells treated with ATR inhibitor or lacking ATR protein (Figure 13A and 13B). In vitro
co-IP experiment (Figure 15D) showed that ATR binds to PARylated PARP1, as much
less ATR binds to PARG-treated PARylated PARP1.The result of the in vitro
PARylation assay (Figure 15A) suggests the mechanism that ATR-PARP1 binding itself
may play a role in suppressing the formation of PAR polymers. As shown in Figure 15A
lane 2, lane 3 and lane 4, adding purified ATR protein (without ATRIP and ATP) already
inhibited the PARylation activity of PARP1, which shows the suppression of formation
of full-length PAR polymers. Furthermore, ATR-PARP1 binding is induced in co-IP
buffer containing Ca2+ as shown in Figure 15B and 15C. The results indicate that PARP1
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hyper-activation is Ca2+ dependent. But why Ca2+ overload induces ATR-PARP1 binding?
PAR is highly negative charges due to the two phosphate groups of each ADP-ribose
subunits (Figure 5) (Leung 2014). Those negative charges PAR polymers intrinsically
tend to bind to positive charged protein surface. May ATR have the positive charged
surface to bind to the shortly PAR-modified PARP1 to inhibit the further extension of
PARP1 spatially due to ATR is a big protein. As a result, a hypothesis was proposed that
ATR tends to bind the short PAR-modified PARP1to spatially inhibit the PARylation
activity of PARP1.
In 1995, glutamic acid (E) 988 on the C-terminal catalytic domain of PARP1 was
found to be essential for the synthesis (specific the elongation) of enzyme-linked PAR
polymers. E988Q, E988A and E988K mutant PARP1 proteins were almost devoid of
elongation activity (2800-fold reduction) (Rolli et al. 1997; Chapman et al. 2013).
Mammalian expression plasmids PARP1-E988Q and PARP1-E988K were built and will
be used for future determination of the mechanism of ATR binding to PAR modified
PARP1.

The Anti-Necrosis Function of ATR Is ATR Kinase Activity Dependent and ATRIP
Independent
The present work shows that the kinase activity of ATR is needed for its antinecrosis function. Ionomycin-activated kinase activity of ATR (Figure 14A) and
ionomycin-induced ATR-PARP1 binding is ATR kinase activity dependent (Figure 14B).
Cells containing ATR-KD protein are much more sensitive to ionomycin-induced
necrosis than cells containing ATR-WT protein (Figure 14C-E).
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It was reported that ATRIP in the nucleus forms a complex with ATR and is
essential for the DNA damage checkpoint activity of ATR (Cortez 2001; Burrows and
Elledge 2008). Figure 15A (lane 2, 3, 6 and 7) shows that purified ATR can suppress
Ca2+-activated PARylation activity of PARP1, while purified ATR cannot suppress
activate oligo (mimic DNA damage)-activated PARylation activity of PARP1. It
indicates that the mechanism of ATR in response to DDR and NDDR is not same. Since
ionomycin induces NDDR in cells, whether ATRIP is dispensable for the novel role of
ATR needed to be studied via more research study.
Since ionomycin treatment activates the kinase activity of ATR and induces ATR
physically interacting with PARP1, which indicates that ATR phosphorylates PARP1
while they binding. Even though the data of Figure 15A shows that, without ATP and
ATRIP, purified ATR could inhibit the extension of PARylation of PARP1. That might
be the ATR-PARP1 binding itself is to inhibit the PARylation activity of PARP1
spatially. The kinase activity of ATR does play a role in helping ionomycin-treated cells
from necrosis. Figure 16 shows that threonine 368 on PARP1 is a candidate
phosphorylation site via mass spectrometry. Mammalian expression human PARP1T368A plasmid was built for future mechanism research. Based on the SQ/TQ motif of
ATR (Traven and Heierhorst 2005), 6 candidate phosphorylation sites were found on
PARP1 as shown in Table 4. The PARP1-S179A, -T325A, -S721A, -S727A, -S874A and
–S911A plasmids were built for future mechanism research as shown in Figure 17.
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Summary
The present work reveals that ATR plays a role in suppressing the ionomycininduced necrotic cell death is part of NDDR. As summarized in Figure 20, ionomycininduced necrosis is caused by Ca2+ overload-induced hyper-activation of PARP1, which
leads to excessive consumption of NAD+ pool in cells followed by cellular metabolism
(ATP pool) failure. During this process, little or no DNA damage stress is induced as no
DDR markers can be detected. ATR plays a role in suppressing necrosis through physical
interaction with PARP1 and suppresses the excessive consumption of NAD pool. In vitro,
the PARylation activity of PARP1 was inhibited to allow the long full extensive PAR
polymers on itself when ATR together with PARP1 are incubated in the PARylation
reaction buffer. ATR prefers to bind PAR-modified PARP1 instead of MAR-modified
PARP1. The results mentioned above indicate ATR plays an anti-necrosis role in
ionomycin-induced necrotic cell death.

Figure 20: ATR plays a role in NDDR wherein it is able to suppress ionomycin-induced
PARP1-mediated necrosis.
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APPENDICES

ATR Protein Purification
It is demonstrated in our lab that DNA damage (particularly UV damage) induced
an electrophoretic mobility shift of cytoplasmic but not nuclear ATR. The inducedcytoplasmic ATR migrated slower in 3%-8% gradient SDS-PAGE than the nuclear or
non-induced cytoATR and is designated as ATR-H relative to the latter (ATR-L). Two
lots of recombinant ATR were purified from HEK293T cells transfected with a
pcDNA3.1-ATR WT overexpression construct. As shown in Figure 21A, the purified
ATR co-migrated with the ATR-H form using WB analysis. Using Pierce 660 nm protein
assay as shown in Figure 20C, the purified ATR-H was 124 μg/mL. And the purified
ATR-H can be visualized by coomassie blue staining (Figure 21B) (Figures 21A and 21B
are copied from Hilton et al. 2015).

107

Figure 21. ATR protein purification. (A) WB analysis of two lots (1 and 2) of
recombinant ATR protein using anti-ATR antibody. Recombinant ATR protein was
purified from HEK293T cells using anti-FLAG antibody. Purified ATR has the same
electrophoretic mobility as endogenous ATR-H from UV-treated HCT116 cells. (B)
Recombinant ATR purified from HEK293T cells, followed by coomassie blue staining of
purified ATR on SDS-PAGE gel. (C) Standard curve for measurement of purified ATR
using Pierce 660 nm protein assay.

siRNA Knockdown of Peptidylprolyl Isomerases in A549 Cells
Since the observation of ATR-H in the UV-treated cytoplasmic fraction, it is of
interest to know how it is formed after irradiation. It was shown that, upon DNA damage,
phosphorylation did not cause the ATR shift (Liu et al. 2011, Nam et al. 2011). The same
was true for modifications by glycosylation, ubiquitinylation, sumoylation,
palmitoylation, prenylation, and N-myristoylation. Also, ATR-H is not a biosynthetic
precursor to ATR-L as it occurred with translation inhibitors. Alternatively, this mobility
shift may reflect a backbone conformational change that persists in SDS-denaturing gel
electrophoresis. Since isomerization of peptidyl-propyl bonds may confer a backbone
conformational change (Zhou and Lu 2016), possible isomerization of ATR was
examined. Prolyl isomerases cyclophilin-40 (CyP40), cyclophilin-A (CyPA), and Pin1
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are known to be active in the cytoplasm. As shown in Figure 22, Pin1 depletion resulted
in formation of ATR-H even in the absence of UV (comparing ratios of ATR-H to ATRL in lane 1 versus lane 7), depletion of CyP40 and CyPA had little effect (lane 1 versus
lanes 3 or 5) (copied from Hilton et al. 2015).

Figure 22. siRNA knockdown of indicated peptidylprolyl isomerases in A549 cells. It
shows that ATR-H formation increases in the cytoplasm of non-irradiated A549 cells
only after Pin1 knockdown (lane7) (copied from (Hilton et al. 2015).

Pin1 Protein Purification
GST-tagged Pin1 construct was transformed into E.coli (BL21 (DE3)) and
expression induced with IPIG (1 mM) as indicated in Figure 23A. Induction of GST-Pin1
expression at 30°C was chosen based on the result of coomassie blue staining of cell
lysate on SDS-PAGE gel (Figure 23A). GST-Pin1 was induced to express at 30°C for
indicated period (Figure 23B). 5 hours incubation period was chosen for GST-Pin1
expression based on the result of coomassie blue staining of cells lysate on SDS-PAGE
gel as shown in Figure 23B. Figure 23C shows the coomassie blue staining of purified
GST-Pin1 protein in 10% SDS-PAGE gel. Purified GST-Pin1 protein is 500 μg/mL in 10%
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glycerol and 1000 μg/mL in 50% glycerol after overnight dialysis based on the standard
curve built via using Pierce 660 nm protein assay, as shown in Figure 23D.

Figure 23. GST-Pin1 protein purification from E.coli (BL21 (DE3)). (A) GST-Pin1
protein was induced to express in E.coli (BL21 (DE3)) at indicated incubation
temperature, followed by coomassie blue staining of cell lysate on SDS-PAGE gel. (B)
GST-Pin1 were induced to express in E.coli (BL21 (DE3)) at 30°C with indicated
incubation period, followed by coomassie blue staining of cell lysate on SDS-PAGE gel.
(C) Coomassie blue staining of purified GST-Pin1 on SDS-PAGE gel. (D) Standard
curve for measurement of purified GST-Pin1 using Pierce 660 nm protein assay.
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Sequence Alignment of BH3 Domains in Bcl2 Family Proteins with ATR Protein
Protein sequence alignment of ATR with several Bcl2 family members reveals
that ATR contains three potential BH3-like domains, a hallmark of Bcl2 family proteins
(copy from Hilton et al. 2015).

Figure 24. Sequence alignment of BH3 domains in Bcl2 family proteins with ATR
protein. In the consensus BH3 sequence, ɸ represents a hydrophobic residue, Z a
hydrophilic residue, D/E an acidic residue, A/G a small residue, K/R a basic residue, and
X any residue. Three candidate BH3 domains were observed: ATR (175-187), ATR (462474), and ATR (2345-2357) (copy from Hilton et al. 2015).

ATR cDNA Fragment (A359-N484, ATRf) Subclone
It is demonstrated that the backbone change of ATR by peptidylprolyl isomerase
Pin1 is the reason for the mobility shift of cytoplasmic ATR after UV treatment. S428
P429 site on ATR is the substrate site of Pin1 for the backbone change. It is of interest to
subclone the ATR fragment (A359-N484, ATRf) and ATRf containing site mutation of
P429A, containing BH3-like domain and Pin1 isomerization site, in plasmid vector for
protein expression and structure analysis. Compared with ATR protein which is
composed of 2644 aa, the ATRf and ATRf containing site mutation of P429A are much

111

small with 126 aa, which may be more easy and convenient for structure and mobility
shift analysis. ATR fragment (A359-N484, ATRf) was chose for subcloning into vector
pTYB2. pTYB2 is an E. coli cloning and expression vector (7474 bp) used to insert the
target protein into its multiple cloning sites (MCS). This results in the fusion of the Cterminal of the target protein to the N-terminal of the intein tag. IMPACTTM Kit allows
the thiol-induced self-cleavage of the intein releases the target protein form the chitinbound intein tag, resulting in a single column purification of the target protein. As shown
in Figure 25A, NheI and XhoI in the MCS of vector pTYB2 were chosen for subcloning
the ATR fragment (A359-N484). As shown in Figure 25B, agarose gel electrophoresis
showed undigested and single restriction enzyme-digested or double restriction enzymedigested vector pTYB2. ATRf PCR fragment is also shown in Figure 25B. The results
indicate that both vector pTYB2 and ATRf PCR fragments are corresponding to the
expected sizes. After the subcloning, pTYB2-ATRf was restriction enzyme double
digested by NdeI and XhoI, followed by agarose gel electrophoresis of pTYB2 with same
double digestion and the ATRf PCR fragment. Figure 25C shows that pTYB2-ATRf
construct was built, as the digested big fragment from pTYB2-ATRf is the same size as
the digested pTYB2 (lane 4, 5, 6 vs lane 2) and the digested small fragment from pTYB2ATRf is the same size as the ATRf PCR fragment. The pTYB2-ATRf construct sent out
for sequencing to check whether the ATRf PCR fragment containing the correct ATR
fragment sequence or not. As shown in Figure 25D, the ATRf subcloned into vector
pTYB2 is 100% match to the ATR (A359-N484) fragment cDNA sequence. The green
color bar indicated the identity. As shown in Figure 25E and 25F, the C-terminal of the
His-tag connects to the N-terminal of the ATRf fragment, and NdeI and XhoI restriction
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sites on vector pTYB2 are on pTYB2-ATRf construct. The results confirm that ATRf
fragment is inserted in pTYB2 vector and with His-tag at the N-terminal of ATRf
fragment. The same method was employed for subcloning the ATR fragment (A359N484) containing mutagenesis at site P429A into vector pTYB2. Figure 25G shows the
subclone works as ATR fragment (A359-N484, P429A) is 100 matches the ATR (A359N484) fragment expect P429A mutation.

Figure 25 (continued to the next page)
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Figure 25 (continued to the next page)
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Figure 25. ATR cDNA fragment (A359-N484, ATRf) subclone. (A) The multiple cloning
sites (MCS) of pTYB2 vector (modified from the datasheet of pTYB2 vector,
https://www.neb.com/products/n6702-ptyb2-vector). (B) Agarose gel electrophoresis of
vector pTYB2, with or without restriction enzyme digestion as indicated, and ATR
cDNA PCR fragment (A359-N484, ATRf). (C) Agarose gel electrophoresis of pTYB2,
pTYB2-ATRf with or without restriction enzyme double digestion. (D) Sequence
alignment of cDNA of ATRf with construct pTYB2-ATR (A359-N484). (E) The His-tag
and NdeI enzyme cDNA sequence on construct pTYB2-ATR (A359-N484). (F) The
XhoI enzyme cDNA sequence on construct pTYB2-ATR (A359-N484). (G) Sequence
alignment of cDNA of ATRf with construct pTYB-ATRf P429A.

Cellular Ca2+ concentration measurement after ionomycin treatment in ATR+/+ and
ATRflox/- cells
Ionomycin, a Ca2+ ionophore, was used in research to induce necrosis by
increasing intracellular Ca2+ concentration (Hermann 1978; Vaseva et al. 2012). As

115

shown in Figure 26, the intracellular Ca2+ concentration began to increase immediately
upon ionomycin added into cell culture media. The Ca2+ concentration reached to 700 nM
in ATR-proficient cells and almost reached to 1000 nM in ATR-deficient cells after 10
minutes of ionomycin incubation. Intracellular Ca2+ concentration began to drop
immediately after the cells were placed in Ca2+-free media with ionomycin. The result
shows that the ionomycin treatment does generate an intracellular Ca2+ overload.

Figure 26. Cellular Ca2+ concentration measurement after ionomycin treatment in ATR+/+
and ATRflox/- cells. ATR+/+ and ATRflox/- cells were incubated with intracellular calcium
indicator Fura-2 before ionomycin treatment. Intracellular Ca2+ concentration was
measured for 10 minutes once ionomycin was added to Ca2+ containing cell culture
media, followed by another 10 minutes of measurement of ionomycin treatment in nonCa2+-contained media. The experiment was done by Dr. Robert Wondergem.

Testing of ATR-WT and ATR-KD Protein Function in Cells
The WB analysis results of Figure 27A and 27B shows that doxycycline
incubation induces expression of ATR-WT and ATR-KD protein in ATR-WT and ATR-
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KD cells. ATR-KD is ATR protein loss its kinase activity since there is none or little
phosphorylation of Chk1 at serine 345 detected after UV treatment.

Figure 27. Test of kinase activity of ATR-WT and ATR-KD proteins in U2OS ATR-WT
and ATR-KD cells. (A) U2OS ATR-WT cells were incubated with doxycycline for 16-24
hours to induce ATR-WT expression. WB analysis of ATR protein expression using antiATR antibody. (B) ATR-WT and ATR-KD cells were induced to express ATR-WT and
ATR-KD proteins respectively as mentioned in A, followed by UV-C treatment with 2
hours recovery. WB analysis of DDR role of ATR using anti pChk1-S345 antibody.
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